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To investigate white matter pathology, I examined glial cells on a cellular level. 
Neuropathologically-verified CTE samples were compared to RHI-experienced controls, 
with both groups containing samples with and without depressed mood. CTE with 
depressed mood had reduced myelin and increased neuroinflammatory peripheral cells 
compared to non-depressed CTE and contained increased numbers of microglia 
compared to non-depressed CTE and control samples. Using single-nucleus 
transcriptomics in neuropathologically-verified CTE samples compared to matched RHI-
naïve controls,  OL loss, iron aggregates, OL iron trafficking dysregulation, and two 
distinct astrocyte subpopulations were detected in CTE white matter. AD white matter, 
compared to the same control samples in the same brain region, was also depleted of OLs 
by single-nucleus transcriptomics. However, OLs did not demonstrate iron-related 
transcriptional profile like those in CTE and, in further contrast, displayed increased 
numbers of microglia and astrocytes.  
Together, these findings implicate previously uncharacterized white matter glia in 
the neurodegenerative process of CTE and AD and further elucidate the etiology of 
neurodegeneration-related symptoms in CTE. These findings may aid in the development 
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 CHAPTER I – INTRODUCTION 
Tauopathies are a class of progressive neurodegenerative diseases wherein 
endogenous tau protein is misfolded and accumulates pathologically in neurons and glial 
cells, forming aggregates like neurofibrillary tangles (NFTs; intracellular accumulations 
of p-tau in neurons)1. The diagnostic misfolded tau protein lesions of tauopathies, like 
chronic traumatic encephalopathy (CTE) and Alzheimer’s disease (AD), are located in 
the upper layers of the cortex of the brain, the neocortex. However, subcortical white 
matter changes and glial pathology are consistently observed and may contribute to the 
neurodegenerative process2,3. 
In CTE, glial cells such as microglia, macrophages, and astrocytes are known to 
react to sites of damage. CTE, a tauopathy that is triggered by repetitive head impacts 
(RHI), is defined neuropathologically by the presence of misfolded, hyperphosphorylated 
tau protein (p-tau) aggregates in neurons, astrocytes, and cell processes at the depths of 
cortical sulci around small cortical vessels2. The observed pattern of perivascular NFTs 
and astrocytic p-tau pathology at the depth of the cortical sulci around small blood 
vessels is hypothesized to be the consequence of shearing stress and vascular damage 
from RHI4. Astrocytic proliferation and activation is common around cortical p-tau 
lesions and appears in inconsistent locations in white matter5,6. This astrocytic response 
around perivascular p-tau pathology may exacerbate the RHI-mediated injury to blood 
vessels. Heightened blood brain barrier (BBB) permeability after vascular injury from 






infiltration of peripheral cells and substances11. This chronic deficit of the BBB is 
evidenced in CTE white matter tissue by fibrinogen and IgG infiltration from vasculature 
and white matter hemosiderin-laden macrophages, a common feature of CTE which 
indicates the presence of peripheral hemoglobin12–14. In conjunction with astrocytic 
activation, microglial activation is also observed around cortical p-tau lesions in CTE and 
in spotty white matter locations5,14. When microglia are activated, they proliferate and 
produce neuroinflammatory and neurotoxic substances that form reactive oxygen species 
(ROS) and reactive nitrogen species (RNS)15. Nitric oxide (NO), neuroinflammatory 
cytokines, chemokines, and super oxide free radicals cause neuroinflammation and 
damage to particularly vulnerable populations of vascular cells and adjacent tissue 
areas15–19. In CTE, increased microglial activation has been found to significantly 
increase cortical p-tau pathology20, likely through these neuroinflammatory pathways. 
Glia in CTE play a role in the neurodegenerative process in the cortex, but their specific 
roles in white matter degeneration are poorly defined. Furthermore, certain glial cell 
types that tile the brain and proliferate in white matter, like oligodendrocytes (OLs) and 
oligodendrocyte precursor cells (OPCs), are unexplored on both a cellular and molecular 
level in CTE. 
Multiple glial cell types are also thought to be a contributing factor to the 
progression of other tauopathies. AD is an age-related neurodegenerative tauopathy that 
is characterized by the presence of b-amyloid (Aβ) positive neuritic plaques and NFTs in 






least one form of AD, familial AD, in vivo measures of white matter myelination are 
abnormal before the onset of cortical pathology22. Glial cells in AD react to sites of 
pathology and are associated with myelination changes23. Reactive astrocytes encompass 
Aβ neuritic plaques and interact with neurons containing NFTs, especially as the disease 
increases in severity24–28. Reactive astrocytes are widespread in AD and have been found 
to be a marker of myelin loss in postmortem human samples29. Microglia also have 
abnormalities in AD. Reactive microglia, which also surround Aβ neuritic plaques, are 
thought to accelerate the neuroinflammatory process incited by p-tau and Aβ pathology. 
Reactive microglia in AD express cytotoxic and neuroinflammatory substances and may 
demonstrate a loss-of-function mutation that drives a failure to phagocytose substances 
like Aβ, a primary role of microglia30–34. Similar to CTE, OLs and OPCs are under 
characterized in AD. In postmortem samples, AD is associated with a global loss of 
OLs35,36. Animal models of AD suggest that OL loss may be driven by Aβ toxicity and a 
disruption of the maturation process of OPCs to replace OLs damaged by Aβ37,38. Glial 
cells are implicated in the neurodegenerative process of AD but require further 
characterization in human tissue to understand their contribution to disease processes.  
In both CTE and AD, decreased white matter integrity is thought to influence 
symptoms. CTE symptoms include a variety of cognitive, motor, behavioral, and mood 
changes. In vivo alterations in the white matter of individuals suspected to have CTE are 
associated with executive disfunction and depression39,40. Reduced myelin integrity in 






to depression symptoms, though no previous studies have directly examined this 
association42. In AD, episodic memory loss and executive dysfunction are associated with 
in vivo white matter changes43,44. The majority of studies associating white matter 
changes to symptoms have been conducted in vivo using imaging methods that are not 
sensitive to individual cell types, rather, they detect alterations to white matter tracts. 
While associations between measures of white matter integrity and symptom presentation 
have been made, the influence of white matter glial cells on white matter degeneration is 
not well defined nor is the relationship between glial cells and neurodegenerative-related 
symptoms.  
The roles of white matter glial cells in neurodegeneration, particularly those in 
CTE and AD, are poorly characterized. While the contributions of OLs and OPCs to the 
degenerative process are well documented in demyelinating diseases like multiple 
sclerosis (MS), they are largely undefined in CTE and AD. Furthermore, astrocytes and 
microglia have never been systematically profiled in white matter brain regions in these 
diseases. To begin to characterize white matter glial cells and their contribution to the 
neurodegenerative process in tauopathies, I examined glial cells on both a cellular and 
molecular level in CTE and AD. In a brain area implicated in depression symptoms in 
both Major Depressive Disorder (MDD) and CTE in vivo, the white matter of the anterior 
cingulate, I used immunohistochemistry (IHC) to investigate the density of several cell 
types related to neuroinflammation and the expression of proteins related to 






individuals with depressed mood and neuropathologically diagnosed with CTE. I also 
leveraged single-nucleus RNA sequencing (snRNA-seq), IHC, immunofluorescence (IF), 
and mRNA fluorescent in situ hybridization (smFISH) to characterize the transcriptional 
profile and cellular presentation of white matter glia in postmortem CTE samples in a 
brain region associated with early CTE pathology. I also conducted the same snRNA-seq, 
IHC, IF, and smFISH experimental techniques on postmortem white matter from AD 
samples acquired the same brain region in a preliminary study to compare and contrast 
the cellular and transcriptional findings of white matter glia between AD and CTE. By 
exploring the cellular and transcriptional profile of white matter nuclei in CTE and AD, 
where glial cells are abundant, new determinations might be established in the roles of 
glia in neurodegenerative processes. 
Chronic Traumatic Encephalopathy 
CTE is a neurodegenerative tauopathy triggered by exposure to RHI such as that 
experienced in contact sports, domestic abuse, and military service5,45,46. The incidence of 
CTE is unknown among the general population, though it is estimated that CTE could 
affect approximately 10% of current and former American professional football 
players47,48. There are no definitive biomarkers49,50, established genetic risk factors45,51, 
diagnostic in vivo imaging52–54, or clinically adopted diagnostic criteria55,56 for diagnosing 







Upon postmortem examination of brain tissue, white matter and glial cell 
abnormalities are consistent features of CTE. Common structural findings in CTE include 
reduced brain weight, cortical and white matter atrophy, dilated ventricles, septal damage 
(fenestrations, perforations, and/or cavum septum pellucidum), and pallor of the 
substantia nigra and locus coeruleus2,5,57. Diagnosis of CTE is completed through 
examining specific brain areas at a cellular level with IHC and histological staining 
techniques. The pathognomonic lesion of CTE is observed in an irregular deposition 
pattern of p-tau aggregates in astrocytes, neuronal cell bodies, and neuronal processes 
around small blood vessels2. These lesions often present in an irregular pattern and are 
located at the depths of cortical sulci in the superficial cortical layers II and III2. Apart 
from pathognomonic p-tau lesions, other supportive features of CTE include both cortical 
and white matter pathology.  
White matter in CTE demonstrates abnormal neurodegenerative-related proteins, 
glial abnormalities, and axonal morphology alterations. Astrogliosis, 
hyperphosphorylated TAR DNA-binding protein 43 inclusions ((pTDP43); a pathological 
protein accumulation found in other tauopathies and motor neuron disease), and 
microgliosis are observed histologically in both the cortex and white matter of CTE58,59 
(Figure 1, right). Hemosiderin-laden macrophages are characteristically found in the 
absence of p-tau pathology around small vessels in white matter, even in the earliest 
stages of disease progression58,59. While perivascular neuronal and astrocytic p-tau is 







throughout the brain5,63 (Figure 1). The original site (or sites) of the pathognomonic 
perivascular lesions of CTE are typically located in the locus coeruleus and the depths of 
sulci in the superior, dorsolateral, or lateral frontal cortices in McKee Stage I (mild 
disease)5,63 (Figure 1, left). The appearance of an additional number and larger size of 
sulcal epicenters of p-tau lesions in the frontal lobe occur in McKee Stage II CTE (mild 
disease)5,63 (Figure 1, left). Advancing p-tau pathology in the brain stem (locus coeruleus 
and nucleus basalis of Meynert) is also observed in Stage II5,63 (Figure 1, left). McKee 
Stage III CTE (severe disease) is characterized by p-tau degeneration in the amygdala 
and hippocampus, dense p-tau pathology throughout multiple brain stem regions, and p-
tau inclusions in the frontal, insular, temporal, and parietal cortices5,63 (Figure 1, left). 
McKee Stage IV (severe disease) presents with p-tau lesions throughout the medial 
temporal lobe, diencephalon, and brainstem5,63 (Figure 1, left). The brain areas affected 
by CTE p-tau pathology as the disease progresses correlate broadly with symptoms 
profiles, though this is an area of current research and refinement5,63. 
While symptom presentation has not been formally correlated with CTE stage, 
there are many symptom correlates to postmortem and in vivo white matter alterations 
after RHI exposure alone and in CTE. The symptoms of CTE begin approximately a 
decade after cessation of RHI exposure and include a heterogeneous combination of 
cognitive, behavioral, mood, and motor symptoms14,56,64,65. A proportion of individuals 
with CTE experience parkinsonism, which is associated with advanced CTE5. Cognitive 






common and early symptoms of CTE, as are mood and behavioral symptoms such as 
depression, hopelessness, explosivity, and disorderly behavior42,47,64. Current in vivo and 
postmortem observations in humans after head injury, in suspected CTE, and in 
neuropathologically confirmed CTE suggest that white matter may also contribute 
symptom presentation39,40,66–68. RHI exposure alone may be sufficient to produce both 
white matter abnormalities and induce depressive symptoms.  
General patterns of white matter changes after RHI in humans identify in vivo 
imaging alterations and mood symptoms after both RHI and concussive brain injuries69–
73. White matter diffusivity changes, indicating impairment in the normal anisotropic 
water diffusion of white matter74, occur acutely after sports-related concussion and 
maintain irregular diffusion patterns for at least 6 months after injury, even after 
concussion symptoms resolve to the levels of control athletes66,67. Specifically 
investigating the white matter of the frontal lobe, one study identified white matter 
diffusivity changes as predictive of the presence of behavioral symptoms such as 
depressed mood, anhedonia, and irritability 12 months after RHI exposure68. While 
diffuse white matter changes are associated with RHI exposure and mood symptoms, 
specific white matter structures and tracts related to CTE pathology also contain in vivo 







another study only examining individuals with a history of RHI, reduced fractional 
anisotropy in U-fibers and significantly slowed processing speed were found compared to 
controls79. Other studies investigating single TBIs identify the gray-white matter interface 
as a common location of computerized tomography- (CT-) evident lesions and blood flow 
alterations detected by magnetic resonance imaging (MRI), which were associated with 
cognitive and mood symptoms80,81. White matter alterations after RHI, specifically those 
localized to the frontal lobe and U-fibers, are present and influence cognitive and mood 
symptoms after injury.  
CTE white matter alterations in both postmortem tissue and in vivo studies also 
have correlations to symptoms. One in vivo study conducted in individuals with 
suspected CTE detected frequent white matter signal abnormalities (WMSAs), MRI-
evident lesions associated with increased age, cognitive decline, and small vessel 
ischemic disease39,82. Increased size of WMSAs was associated with impaired executive 
function and slowed psychomotor speed39. Another study found increased likelihood of 
dementia associated with increasingly severe postmortem DLF white matter rarefaction, 
myelin loss that is assessed semi-quantitatively, in CTE41. Using postmortem MRI scans, 
DLF white matter in CTE has been found to demonstrate decreased axonal integrity in U-
fibers, as predicted in the Ghajari et al. computational model62 and supported by reports 
of gliosis along the gray-white matter interface in postmortem examinations of CTE 






cognitive symptom presentation and specifically identify DLF demyelination as a locus 
of dementia symptoms in CTE.  
In addition to cognitive deficits and dementia, white matter changes in CTE are 
associated with depression symptoms. One study examining former American football 
players in vivo found an association between decreased fractional anisotropy, indicative 
of abnormal myelin integrity83, in multiple white matter tracts (uncinate fasciculus, 
forceps minor, superior longitudinal fasciculus, and frontal aslant tract) to increased 
levels of self-reported depression symptoms40. Some of these white matter tracts, like the 
uncinate fasciculus and frontal aslant tract, are associated with both depression and CTE 
pathology. The anterior cingulate white matter (BA25), which partially consists of the 
uncinate fasciculus tract84, is highly implicated in treatment resistant MDD and is 
hypothesized to play a role in mood symptoms in CTE42,85–91. Additionally, the frontal 
aslant tract consists part of DLF white matter (specifically BA8), which has documented 
myelin loss, U-fiber axonal integrity deficits, and glial morphological changes in 
CTE41,61,62,92. While DLF tissue is one of the first locations of perivascular p-tau lesions 
and has many documented pathological abnormalities, BA25 has never been focally 
investigated in CTE5,60,63. Furthermore, neither region has been characterized in the 
context of depression symptoms in CTE42. 
Chronic Traumatic Encephalopathy Summary 
CTE is a neurodegenerative tauopathy that results from exposure to RHI. CTE not 






demonstrates profound changes to glial cells, axons, and white matter integrity at every 
stage of CTE. White matter changes are associated with cognitive and depression 
symptoms and are detectable both in postmortem tissue samples and in vivo in DLF white 
matter and U-fibers. Characterization of both of these brain areas, BA25 and DLF white 
matter, are merited to more fully understand the contribution of white matter to disease 
progression and symptom presentation. Determining the cellular and transcriptional 
profile of white matter glial cells in CTE may lead to a better understanding of the 
biological mechanisms behind CTE pathology and the etiology of CTE symptoms. To 
address this gap in knowledge, I completed two studies using IHC and snRNA-seq, 
respectively, in postmortem brain tissue samples in two white matter regions associated 
with depression symptoms in CTE: BA25 white matter and the U-fibers of DLF tissue40.  
Alzheimer’s Disease  
AD is the most common form of neurodegenerative disease and almost 
exclusively affects individuals over the age of 6593. Every year, approximately one 
million people are diagnosed with AD and there are no treatments94. Late onset AD, 
which accounts for 90% of all diagnosed AD cases, has a highly complex and fully 
undetermined set of etiologies which involve many risk genes, including the 
apolipoprotein E (APOE) ε4 allele and other genes that regulate cholesterol metabolism, 
p-tau production, immunity, and amyloid precursor protein (APP) expression95. AD is 
only definitively diagnosed postmortem and is defined neuropathologically by both the 
presence of NFTs and Aβ neuritic plaques in many locations of the brain in certain 






The diagnosis of AD is confirmed after examining specific brain areas with IHC 
and histological staining techniques against p-tau, Aβ, and APP in the brainstem 
(midbrain, pons, and medulla oblongata), cerebellar cortex and dentate nucleus, thalamus 
and subthalamic nucleus, basal ganglia with nucleus of Meynert, hippocampus with 
entorhinal cortex, anterior cingulate cortex, amygdala, middle frontal gyrus, superior and 
medial temporal gyri, inferior parietal lobule, occipital cortex, and white matter 
surrounding the anterior, medial, and posterior cerebral arteries97. Pathology in those 
regions is staged using the “ABC” scoring system, which gives a Aβ plaque score (A), a 
NFT stage (B), and a neuritic plaque score (C) using standardized methods97. This 
staging process is a combined metric of previously defined staging criteria for different 
neuropathologic aspects of AD97. Aβ plaques (A) are evaluated using Thal phases98, 
Braak staging (B) evaluates NFT location and development21,99, and neuritic plaque 
scores (C) are determined by the Consortium to Establish a Registry for Alzheimer’s 
disease (CERAD) criteria100. In AD, pathology is thought to arise before the onset of 
clinical symptoms. AD progresses from asymptomatic pre-clinical stages (Braak Stages 
a-c) with aberrant protein aggregation to a symptomatic presentation with progressive p-







disease102. Before symptoms become severe, individuals experience mild cognitive 
impairment103. Eventually, AD presents in clinical stages of increasingly severe 
symptoms and p-tau pathology (Braak Stage I through Stage IV; Figure 3) often resulting 
in profound dementia102. 
White matter neuropathological changes have been described and are present in at 
least 50% of AD cases, however few studies focusing on white matter pathological 
processes have been conducted in AD36. White matter atrophy, reduced white matter 
integrity, reactive astrocytosis, microgliosis, myelin and axonal loss, reduction of OL cell 
number, and soluble Aβ in white matter have been documented36,37,104. In vivo studies 
identify associations between demyelination and cortical p-tau load which are consistent 
over multiple brain lobes and may suggest that white matter changes in AD are 
subsequent to cortical damage from p-tau and Aβ pathology105–108. However, one study 
identifying in vivo white matter diffusivity abnormalities before cortical pathology in a 
familial form of AD proposes that white matter changes contribute to disease progression 
earlier than expected22. While p-tau pathology primarily localizes to the cortex in AD, 
NFTs and glial tangles (in both astrocytes and OLs) are present in white matter108,109. 
While many studies have characterized the cortical pathology of AD, white matter cell 
types like OLs and OPCs are understudied. Though microglia and astrocytes are foci of 
many investigations of cortical tissue, their presentation in white matter and contribution 






Additionally, white matter changes in AD are associated with symptom 
presentation. In vivo white matter abnormalities are associated with AD symptoms such 
as executive disfunction and episodic memory loss43,44. DLF white matter and U-fiber 
alterations, as in CTE, are specifically associated with symptoms. In all stages of AD, 
myelin thinning in DLF U-fibers is associated with reduced cognitive functioning in 
vivo110. With white matter abnormalities related to symptoms, potentially present early in 
disease progression, and observed in the majority of AD cases, the pathological processes 
occurring in white matter in AD warrant additional investigation. 
Alzheimer’s Disease Summary 
 AD is the most common neurodegenerative disease and has a complex and largely 
undetermined etiology. The neuropathological presentation of AD comprises of Aβ 
neuritic plaques and NFTs throughout the cerebral cortices, medial temporal lobe 
structures, and brainstem. White matter pathology in AD is not well characterized but 
includes inflammatory and axonal changes, which are associated with AD symptoms and 
severity of cortical pathology. Examining the transcriptomic changes that occur in AD 
and comparing those observations to CTE white matter may more fully elucidate the 
similarities and differences between tauopathies and begin to explain the relationship of 
white matter and cortical pathology in AD. To address this goal, I completed a 
complementary snRNA-seq study in AD postmortem brain tissue samples from the U-
fibers of DLF tissue, an area associated cognitive disfunction in AD, for comparison to 







Single-Nucleus Transcriptomic Analyses in Neurodegenerative Disease 
Single-Cell and Single-Nucleus RNA sequencing 
Single-cell RNA sequencing (scRNA-seq) is a highly parallel, high-throughput 
experimental assay for generating RNA sequencing transcriptomic profiles for individual 
cells. A single scRNA-seq experiment is capable of generating transcriptomic profiles for 
thousands of cells simultaneously from complex tissue types, including human brain 
tissue111–115 (Figure 4). Recently, the technique was expanded to single-nucleus RNA-
sequencing (snRNA-seq), allowing for the generation of transcriptomic profiles of 
complex tissues in which individual cell sequencing is currently impossible, such as those 
derived from frozen human postmortem brain tissue116–123. The advent of snRNA-seq has 
accelerated the ability of researchers to understand the differential contribution of 
individual cells to disease pathology in postmortem brain tissue.  
Single-nucleus RNA sequencing is performed by isolating a tissue of interest and 
enzymatically and mechanically dissociating intact cell nuclei from the tissue. Cell nuclei 
are then injected into a first chamber on a microfluidic chip that limits passage to one cell 
nucleus at a time. At the same time, a solution of hydrogel droplets is injected into a 
second chamber on the microfluidic chip. The two chambers merge midway through the 
chip such that a single nucleus comes in contact with a single hydrogel droplet. The 
composition of the hydrogel droplet is such that when the cell nucleus and the hydrogel 






The purpose of snRNA-seq is to sequence the messenger RNA (mRNA) 
transcripts present in each nucleus. By performing this technique, it is possible to 
understand which cells were present or absent, as well as to understand the gene 
transcripts that were in the process of becoming proteins at the time of death. To collect 
these data, the gene transcripts must be sequenced and traced back to its nucleus of origin 
and its sample of origin.  
Each hydrogel droplet contains beads with three populations of ligated 
oligonucleotides. Each population of oligonucleotides performs a specific function. One 
population is specific to the sample of hydrogel droplets in a solution, the second is 
specific to the individual hydrogel droplet, and the third is specific to the bead itself. 
Once all the nuclei are encapsulated in hydrogel droplets, the nuclei are exposed to 
ultraviolet radiation and lysed, thus exposing the mRNA transcripts to the beads and 
oligonucleotides in the hydrogel droplet. The samples of hydrogel droplets then undergo 
a protocol in which each mRNA molecule within a hydrogel droplet is reverse 
transcribed to complementary DNA (cDNA). At the same time, each mRNA molecule is 
also tagged with three of the specific oligonucleotides present in the hydrogel droplet. At 
the end of the protocol, each mRNA molecule has been transcribed to cDNA, and each 
cDNA molecule has been tagged so that the cDNA molecule can be traced to the nucleus 
of origin and the biological sample of origin. Furthermore, each cDNA molecule has 
been tagged with a unique molecular identifier (UMI). In the case that a cDNA molecule 






analyses. Following this sample preparation protocol, cDNA molecules are sequenced by 
next-generation sequencing (NGS) and analyzed.  
The first step in the analysis is to remove each duplicate copy of sequenced cDNA 
molecules by grouping molecules by UMI. If a sequenced molecule with the same UMI 
is present in the data set more than once, the additional UMIs are removed. Next, cDNA 
molecules are grouped by sample of origin. Every cDNA molecule with matching sample 
tags is grouped. For example, a sample of nuclei from a single human subject will be 
grouped together and a sample of nuclei from another human subject will be grouped 
together. Each cDNA molecule derived from the same hydrogel droplet (and by 
extension, the same cell nucleus) is then grouped. Finally, each cDNA molecule is 
aligned to the human genome and annotated to its gene of origin. Each cDNA molecule 
represents expression of a specific gene in the human genome. The resultant data set 
comprises barcodes and gene counts. Each barcode, representing a single cell nucleus, is 
organized by sample of origin. In short, the resultant data set is a transcriptomic profile 
for thousands of individual nuclei derived from several biological samples. Once a data 
set has been generated and it is possible to understand which cell nuclei were expressing 
which genes in various biological samples, it is necessary to group barcodes by 
similarity. This step allows for cell-type identification and comparison of biological 
conditions.  
The first step of organization requires dimensionality reduction by principal 
component analysis (PCA). This step is a first pass grouping of barcodes by how similar 






machine learning algorithm that determines, with statistical certainty, whether the 
groupings from the PCA analysis are accurate. Finally, each barcode comprising a gene 
expression profile is projected into two-dimensional space by t-distributed stochastic 
neighbor embedding (tSNE). This final step generates a plot with barcodes, or cell nuclei, 
organized and colored by clusters. A cluster of nuclei with similar gene expression 
profiles will be one color and another cluster will be another color. Genes that are similar 
in a cluster can be queried and clusters can be labeled by cell type. For example, one 
cluster may express genes that are known to be markers for OLs, while another cluster 
may express genes that are known to be markers for astrocytes. Subsequently, because 
each barcode has been traced to sample of origin, the tSNE projection can be separated 
by condition and the total gene expression of all the nuclei from one condition can be 
compared to the total gene expression of all the nuclei from the other condition by 
differential gene expression analysis. Lastly, differential gene expression analysis can be 
used to compare conditions on the level of individual clusters. For example, the gene 
expression in astrocytes in one condition can be compared to the gene expression of 
astrocytes in the other condition. Taken together, this analysis facilitates an 






Figure 4. Illustration of the inDrop snRNA-seq pipeline. The inDrop pipeline was used in Chapter III and 
Chapter IV of this dissertation111,115. The inDrops platform encapsulates isolated cells or nuclei and prepares 
them for cDNA sequencing. Reproduced and edited with journal permission from: Klein et al. 2015. “Droplet 
barcoding for single-cell transcriptomics applied to embryonic stem cells.” Cell. 
https://doi.org/10.1016/j.cell.2015.04.044.  
Single-Nucleus RNA Sequencing in Neurological Disorders 
Single-nucleus RNA sequencing can be applied by researchers to evaluate cell-
type-specific differences from sequencing profiles of nuclei derived from frozen 
postmortem human brain tissue116–118,120–124. Recently, snRNA-seq investigations of have 
been completed in human psychiatric and neurological conditions including MS, AD, 
autism spectrum disorder, epilepsy, Huntington’s disease, and MDD116–118,120–125. 
Although sequencing profiles were created from cortical nuclei in all but one of these 
previous studies116, glial cells have consistently been identified as both altered in overall 
cell number and transcriptionally perturbed through the application of snRNA-seq156–16. 
In MS, Jäkel et al. found a globally decreased number of OPCs and discovered a 
previously unknown cell type in the OL lineage in both normal appearing white matter 
and all lesion types in MS. Additionally, Jäkel et al. identified mRNA levels specific to 
multiple types of lesions in MS, with increased numbers of cadherin 20 (CDH20)-






containing oxidoreductase (WWOX)-expressing cells identifying chronic active lesions in 
MS. In an analysis of cortical AD tissue, Grubman et al. found that non-neuronal glial 
cells, such as astrocytes, OPCs, and microglia express more APOE transcripts compared 
to control samples, suggestive that glia may have more of a role in the pathogenesis of 
AD than previously thought. Zhou et al. identified fewer transcripts associated with 
myelination, axonal guidance, cytoskeletal function, and maturation of myelin 
(semaphorin-3B (SEMA3B), microRNA 219a-2 (MIR219A2), and stathmin 4 (STMN4)) 
in OLs in AD. These findings demonstrate that the snRNA-seq assay is a viable and 
comprehensive tool for examining postmortem human brain tissue in the context of 
neurodegenerative disease and demonstrates consistent sensitivity to cell number and 
transcriptional changes in glial cell types like microglia, astrocytes, and OL lineage 
cells116,121,125. 
Single-Nucleus RNA Sequencing Summary 
Leveraging snRNA-seq to examine disease states and/or tissues that are poorly 
characterized on both a cellular and molecular level is an ideal application of the 
technology. This assay produces a comprehensive set of transcriptomic data for every 
sequenced nucleus that may inform biological mechanisms and encourages hypothesis 
generation for future studies. Applying snRNA-seq to evaluate glia in neurodegenerative 
diseases like CTE and AD may produce data relevant for uncovering unknown cellular 
processes and cell-type number distribution and prove to be useful for the identification 






Summary of Chapter I 
White matter is a critical area for further research to better understand the role of 
glia in neurodegenerative tauopathies. Studies concluding that white matter changes 
occur after RHI, can persist chronically, and are detectable in CTE highlight the 
importance of profiling white matter on a cellular and molecular level. RHI has direct 
effects on myelin integrity, glial cell processes, and symptomatology. Depressed mood is 
a debilitating and common symptom of CTE that is related to in vivo white matter 
changes after exposure to RHI40,68. To date, no studies have specifically investigated 
white matter pathology, nor its contribution to mood symptoms42,56,64. Furthermore, there 
is little known about the transcriptomic profiles of the glial cells that constitute the white 
matter of CTE and there are no previous studies comparing CTE white matter to that of 
another neurodegenerative tauopathy like AD, which also has known white matter 
alterations. In this dissertation, (1) I characterized the differences between 
neurodegenerative-related protein expression and neuroinflammatory-associated cell 
density of CTE white matter in postmortem samples with and without depressed mood, 
(2) I identified white matter cell number and cell-type-specific transcriptional expression 
patterns in CTE when compared to RHI-naïve controls, and (3) I identified white matter 
cell number and cell-type-specific transcriptional expression patterns in AD when 
compared to RHI-naïve controls. These three chapters contribute to the understanding of 
white matter CTE and AD pathology, elaborate on in vivo findings of the influence of 






of CTE white matter pathology by identifying cell-type specific transcriptional changes. 
Uncovering the molecular and cellular changes in white matter may further define the 
cause of neurodegenerative disease related symptoms, provide valuable insight into the 
mechanism of the development of CTE, and may better characterize the role of white 
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Abstract 
Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease 
characterized by perivascular hyperphosphorylated tau accumulation and associated with 
inflammation, neuronal loss, and gliosis. Symptoms often include depression and 
suicidality; however, to date the neuropathological correlates of these symptoms have not 
been focally investigated. We examined glial, inflammatory, and neurodegenerative 
disease-associated alterations in the white matter of Brodmann Area 25 (BA25) of the 
anterior cingulate cortex, a brain area previously associated with emotional modulation, 
depression, suicide, and antidepressant effects. We found decreased myelin density and 
increased peripheral T-cell numbers in the BA25 region of postmortem brain tissue from 






Compared to repetitive head injury-experienced controls, CTE subjects with depressed 
mood demonstrated higher numbers of microglia. This is the first study to identify 
specific neuropathological features that might underlie psychiatric symptoms in 
individuals with CTE.  
Introduction 
Chronic traumatic encephalopathy (CTE) is a progressive neurodegenerative 
disease associated with exposure to repetitive head impacts (RHI), the symptoms of 
which include cognitive, behavioral, motor, and psychiatric alterations2,5,42,45,46,56. 
Common psychiatric symptoms include depression and suicidality42,47. CTE can only be 
diagnosed with certainty by neuropathological examination of the brain. The 
pathognomonic lesion for CTE is perivascular hyperphosphorylated tau (p-tau) 
accumulation around small vessels at the depth of the cortical sulci2. The initial lesions of 
CTE occur focally in the cortex. With increasing pathological severity, widespread 
neurofibrillary tangles are found in the medial temporal lobe, diencephalon, and 
brainstem2,5. White matter alterations are also found in CTE. Specifically, frontal cortical 
axonal signaling and myelin basic protein levels may be reduced in CTE, in tandem with 
increased cortical axonopathy and reduced myelin-associated glycoprotein levels in 
frontal cortical white matter126. White matter rarefaction has also been independently 
associated with RHI and dementia in CTE41. In addition to loss of myelinated fibers, 
axonal disruption, astrocytic gliosis, hemosiderin-laden macrophages, and p-tau 






cell types and proteins associated with myelin loss have never been investigated in white 
matter in CTE, like cluster of differentiation 8- (CD8-) positive T-cells, which are 
associated with reduced myelin integrity and neurological impairment after traumatic 
brain injury (TBI) and may contribute to a hyper-neuroinflammatory white matter 
environment that may drive the myelin loss observed in CTE10,127,128. Furthermore, 
although gliosis and inflammatory processes have been suggested to underlie CTE 
symptomatology20,50 and are believed to play an active role in demyelination and p-tau 
pathology, cell types like astrocytes and microglia, along with myelin and astrocytic 
proteins like aquaporin-4 (AQP4), have never been examined in this brain region. With 
only one previous study examining white matter integrity and associations to 
symptoms41, the current study aims to characterize a number of cell types and proteins in 
a white matter area associated with depression symptoms.   
The anterior cingulate cortex (ACC) has been implicated in negative emotional 
processing as well as depression and suicidality129–139. This is particularly true for the 
subgenual/subcallosal ACC including the white matter of Brodmann Area 25 (BA25)140. 
The well-characterized connections of BA25 involve cortical and limbic structures, 
including the prefrontal cortex, amygdala, hippocampus, and nucleus accumbens, 
associated with emotional experience and regulation, interoception, and memory141–144. 
Alterations in this region have been found in depressed patients, including volumetric 
loss, decreased glial cell density, and decreased blood flow and metabolism145–149. 






functional BA25 activity150–153, and in functional magnetic resonance imaging studies 
subcallosal cingulate connectivity has been shown to predict response to antidepressant 
medication or cognitive behavioral therapy154. Deep brain stimulation (DBS) in this brain 
region has emerged as an effective treatment for depression even in intractable cases86–
91,155–157. Subcallosal cingulate DBS is most effective in treating depression when three 
white matter tracts (forceps minor, cingulum bundle, and uncinate fasciculus) are 
targeted158,159. In suspected CTE, reduced fractional anisotropy in the uncinate fasciculus, 
a white matter tract which consists part of BA25 white matter84, is associated with 
increased depression symptoms40. Furthermore, white matter-specific alterations in the 
ACC have been found in depressed subjects who died by suicide137–139. BA25 in 
neurodegenerative depression symptoms has been largely unexamined; however, a recent 
case report describes co-presentation of significantly decreased BA25 metabolism with 
severe progressive depression symptoms and suicidality in a young individual with 
Huntington’s disease160. Together these studies suggest BA25 white matter plays an 
important role in depression symptoms and antidepressant response161. As such, BA25 
white matter represents an ideal locus for investigating associations between 
neurodegenerative pathology and depression symptoms in the context of CTE 
neuropathology42. We, therefore, examined inflammation, gliosis, and white matter 
integrity in BA25 and their association with depressive symptoms in subjects diagnosed 
with CTE neuropathologically compared to subjects with CTE without depressed mood 






Immunohistological Characterization of BA25 
The present study characterizes the postmortem neurodegenerative protein and 
glial cell pathology of BA25 white matter in depressed mood (n = 31; n = 12 medicated 
with antidepressants) and non-depressed mood (n = 11) subjects with CTE compared to 
RHI-experienced controls (n = 13) through immunohistochemistry (IHC) and other 
histological staining techniques listed in detail in Appendix Table 1. Further information 
regarding subject group selection and inclusion criteria is listed in Appendix I and subject 
demographics are available in Appendix Table 2. In this study, we examined 
neurodegenerative disease features (e.g., inflammation, gliosis, and pathologic protein 
aggregates), peripheral T-cells, and white matter integrity in this brain region. Findings 
from this chapter not only help define the neuropathological presentation of white matter 
in CTE but ascertain whether any observed white matter differences are associated with 
depressed mood symptoms, suicidality, and/or antidepressant medication use. 
Results 
We compared CTE cases with depressed mood to those without (Figure 5), 
including stratification by antidepressant medication status (Figure 6), compared to non-
neurodegenerative disease controls with and without depressed mood (Figure 7), and 
compared depressed mood phenotypes between both controls and CTE cases (Figure 8). 
Finally, we examined the potential associations between factors of interest and death by 






CTE Depressed Mood Comparison 
A first comparison was conducted between CTE cases with depressed mood to 
those without depressed mood (Figure 5), including stratification by antidepressant 
medication status (Figure 6) to determine the extent of cellular alterations of 
neurodegenerative disease related features within CTE. When comparing CTE cases with 
and without depressed mood (Figure 5), depressed mood cases with CTE had a 
significant increase in the density of cluster of differentiation 8- (CD8-) immunoreactive 
cells (P = 0.0057), corresponding to a 65% increase (Figure 5a-c), as well as decreased 










CTE and Control Mood Comparison 
To examine whether phenotypes of depressed mood in CTE are shared with non-
neurodegenerative depressed mood or if the lack of change between depressed mood in 
CTE was due to a depressed mood phenotype in RHI-experienced controls, an analysis 
with controls split into those with (n = 8) and without (n = 5) depressed mood was 
conducted. Microglial density showed that CTE cases with depressed mood had increased 
microglial density than controls without depressed mood (P = 0.0275), but not controls 
with depressed mood (Figure 8). When stratifying CD8 and myelin analyses by both CTE 
mood groups and RHI mood groups, no significant group differences exist.  
 
 
Figure 6. Microglial density in depressed mood. Non-depressed mood RHI = Dep- RHI, Depressed 
mood RHI = Dep+ RHI, Non-depressed mood CTE = Dep- CTE, Depressed mood CTE = Dep+ CTE. 
Quantification for number of IBA1-positive nuclei per mm2 over the entire white matter sample for each 
subject (n = 5 (Dep- RHI), n = 8 (Dep+ RHI),  n = 11 (Dep- CTE), n = 30 (Dep+ CTE), one-way ANOVA, 







Stratification of Suicide in CTE and Other IHC Analyses  
None of the primary variables of interest were significantly associated with 
suicide. Other proteins or cell types of interest (e.g. b-amyloid (Aβ; Aβ4G8), 
hyperphosphorylated TAR DNA-binding protein 43 (pTDP-43), microtubule-associated 
protein 2 (MAP2), and glial fibrillary acidic protein (GFAP) immunoreactivity; Appendix 
Table 1) did not differ significantly between groups for any analyses  
Discussion 
This study is the first to examine the neurobiological associations of a psychiatric 
phenotype in CTE. We find that alterations in BA25 white matter are associated with 
depressed mood in the context of CTE. Specifically, CTE cases with depressed mood had 
increased CD8-expressing cell density and reduced myelination in BA25 white matter. 
Increased CD8-expressing cell density has also been found in other neurodegenerative 
disorders that have depressed mood as a symptom162–164. Additionally, the current study 
establishes an association between alterations in both a particular region and 
neurobiological phenotypes with a prominent psychiatric feature of CTE. Studies of other 
neurodegenerative contexts have also found alterations in the ACC or BA25 associated 
with depression or suicide133–135, supporting the concept that this region is a locus of 
vulnerability to psychiatric issues in neurodegenerative disease. 
In a recent semi-quantitative study, white matter rarefaction was reported in the 
dorsolateral frontal cortex (DLF) in football players with CTE and was associated with 






have both been associated with amount of football exposure41,165. The current study is the 
first to specifically associate loss of white matter in BA25 with depressive symptoms in 
CTE. In non-neurodegenerative psychiatric studies, loss of white matter and other white 
matter alterations have been associated with suicide, depression, and depressive 
symptoms166–170, including in ACC and adjacent white matter171–173. 
We found that antidepressant medication was associated with decreased AQP4 
expression, which has not previously been reported. AQP4 increases under pro-
inflammatory conditions including neurodegenerative disease174–176 and after TBI177. 
Antidepressants are known to have anti-inflammatory effects in the brain178–180, it is 
plausible that a reduction in AQP4 in antidepressant-medicated CTE cases may be related 
to an anti-inflammatory effect of medication.  
Microglial density was increased for CTE cases with depressed mood. Microglial 
alterations in ACC white matter have also been reported in depressed individuals who 
died by suicide without neurodegenerative disease138. One possible mechanism for 
microglial alterations underlying depressed mood in CTE may be through their 
demonstrated activation of the hypothalamic-pituitary-adrenal axis138,181 (which has a 
strong association with depression182) via secretion of pro-inflammatory cytokines. 
Notably, previous studies of microglial density in DLF cortex did not find alterations in 
microglial density between CTE cases and non-neurodegenerative controls20. It may be 






microglial density in CTE white matter is altered consistently throughout select brain 
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Abstract 
Chronic traumatic encephalopathy (CTE) is a progressive tauopathy found in 
contact sport athletes, military veterans, and others exposed to repetitive head impacts 
(RHI)2,5,14,183–185. White matter atrophy and axonal loss have been reported in CTE but 
have not been characterized on a molecular or cellular level5,61,62. Here, we present RNA 
sequencing profiles of cell nuclei from postmortem dorsolateral frontal white matter from 
eight individuals with neuropathologically confirmed CTE and eight age- and sex-
matched controls. Analyzing these profiles using unbiased clustering approaches, we 
identified eighteen transcriptomically distinct cell groups (clusters), reflecting cell types 
and/or cell states, of which a subset showed differences between CTE and control tissue. 
Independent in situ methods applied on tissue sections adjacent to that used in the single-






be most severely affected in the CTE white matter samples; they were diminished in 
number and altered in relative proportions across subtype clusters. Further, the CTE-
enriched OL population showed greater abundance of transcripts relevant to iron 
metabolism and cellular stress response. CTE tissue also demonstrated excessive iron 
accumulation histologically. Astrocyte alterations were more nuanced; total astrocyte 
number was indistinguishable between CTE and control samples, but transcripts 
associated with neuroinflammation were elevated in the CTE astrocyte groups as 
compared to controls. These results demonstrate specific molecular and cellular 
differences in CTE OLs and astrocytes and may provide a starting point for the 
development of diagnostics and therapeutic interventions. 
Introduction 
Chronic traumatic encephalopathy (CTE) is a progressive tauopathy associated 
with exposure to repetitive head impacts (RHI)2,5,14,183–187. CTE has been reported in 
contact sport athletes, veterans exposed to blast and other mild traumatic brain injuries, 
and victims of domestic abuse5,14,185. The symptoms of CTE include behavioral 
dysregulation, depression, executive dysfunction, memory impairment, and 
dementia5,47,56,64; however, like most neurodegenerative diseases, a definitive diagnosis of 
CTE requires postmortem neuropathological tissue examination. A National Institute of 
Neurological Disease and Stroke (NINDS)/National Institute of Biomedical Imaging and 
Bioengineering (NIBIB) panel defined the pathognomonic lesion of CTE as the 






in an irregular pattern in the cerebral cortex, most prominent at the depths of the sulci2. 
The distinctive p-tau pathology of CTE primarily involves frontal, parietal and temporal 
cortices, medial temporal lobe, diencephalon, and brainstem5,14. Although p-tau 
accumulation in gray matter structures is an essential feature of CTE, there are also 
profound changes in the white matter, including white matter atrophy, rarefaction, myelin 
and axonal loss, astrocytic degeneration, microglial inflammation, microvasculopathy, 
hemosiderin-laden macrophages, and p-tau pathology5,6,61,62,185. Furthermore, white 
matter alterations might play a key role in the production of clinical symptoms in CTE, 
with white matter rarefaction previously shown to be independently associated with 
dementia in CTE5,20,41. 
Previous transcriptomic analyses of CTE have identified dysregulated neuronal 
genes, including the protein phosphatase-encoding gene PPP3CA188, as well as 
alterations in synaptotagmin-1(SYT1), calcium/calmodulin-dependent protein kinase II, 
protein kinase A, protein kinase C, and cell adhesion molecule associated genes189. 
Quantitative proteomic analysis of dorsolateral frontal gray and white matter has shown 
down regulation of axonal signaling pathway proteins and Western blot analysis has 
shown significant reduction in protein levels of oligodendrocyte- (OL-) specific proteins 
(such as myelin-associated glycoprotein, myelin basic protein, and βIV-tubulin) and 
neuronal markers (such as cofilin-1 and βIII-tubulin126). To date, however, no studies 
have systematically analyzed the differential vulnerabilities of individual cell types in 






We sought to explore cell-type-specific mRNA profiles in white matter from 
subjects with neuropathologically verified CTE compared to age-, sex-, and postmortem 
interval (PMI)-matched controls by applying the method of snRNA-seq, in combination 
with complementary in situ histological, immunohistochemical (IHC), 
immunofluorescent (IF), and single-molecule mRNA in situ hybridization (smFISH) 
validation techniques. Our transcriptomic analyses yielded 24,735 individual brain nuclei 
RNA profiles derived from 16 samples ((CTE) n = 8, (Controls) n = 8) and provide a 
resource to help understand the complex cell subtypes, cellular states, and gene 
expression profiles that may contribute to the pathology of CTE. Similar to previous 
reports using snRNA-seq in other neurological diseases and disorders, including 
Alzheimer’s disease (AD), multiple sclerosis (MS), autism spectrum disorder, 
Huntington’s disease, and epilepsy116–118,120–122, our findings–the first at single-nucleus 
resolution–indicate differences in cell types, subpopulations, and gene expression in CTE 
white matter compared to controls. 
Results 
Single-Nucleus RNA Sequencing of Human Postmortem CTE White Matter 
We performed molecular profiling of individual cell nuclei from fresh-frozen 
white matter tissue from the dorsolateral frontal cortex (Brodmann area 8/9; BA8/9). We 
collected nuclei from 16 age- and PMI-matched male individuals (Figure 9a, Appendix 
Figure 1a-d, Appendix I, Methods). Clinical data and demographics are provided in 






Stage II or III CTE2,5,63 and 8 individuals with no neuropathological disease or known 
history of RHI. All 8 CTE subjects were former American football players with no co-
morbid neurodegenerative disease (Appendix Table 3, Appendix I, Methods). BA8/9 was 
selected as it is an area of early and severe p-tau pathology5. Samples with McKee Stage 
II and III CTE were selected for study, reasoning that moderate disease would likely 
reveal transcriptomic changes pertinent to CTE. We report a total of 24,735 droplet-based 
snRNA-seq profiles across 16 subjects with a median of 561 genes and 854 unique 
molecular identifiers (UMIs) per nucleus (Figure 9, Appendix Figure 1e-g, 
Supplementary Table 1). 
For transcriptomic analyses, we collected intact nuclei by mechanical and 
enzymatic dissociation and density gradient ultracentrifugation from 1 cm3, frozen tissue 
blocks (Appendix I, Methods). We collected white matter immediately beneath the 
cortical ribbon at the sulcal depth in order to target the subcortical U-fibers, in which 
pathological abnormalities and axonal microstructural alterations have been observed in 
CTE14,62 (Figure 2, Figure 9a, Appendix Figure 1a). For in situ validations, we collected 
tissue directly adjacent to the sample taken for snRNA-seq transcriptomic analysis 
(Appendix Figure 1a). 
After collecting cell nuclei, we used the inDrops method to encapsulate each 
nucleus for sequencing (Figure 4, Appendix I, Methods). Following sequencing, we 
performed quality control, cell filtering, and computational analysis using the Seurat 
pipeline190,191 to produce single-nucleus transcriptomic profiles of the 8 control and 8 






an integrated t-distributed stochastic neighbor embedding (tSNE) projection yielding 18 
transcriptomically distinct nuclei clusters derived from control and CTE samples (Figure 
9b, left). We mapped clusters to cell types by identifying the cluster-specific presence of 
transcripts encoding specific canonical cell-identity markers: proteolipid protein 1 
(PLP1) for OLs, glial fibrillary acidic protein (GFAP) for astrocytes, versican (VCAN) for 
OPCs, cluster of differentiation 74 (CD74) for microglia, neurogranin (NRGN) for 
excitatory neurons, glutamate decarboxylase 1 (GAD1) for interneurons, and claudin 5 
(CLDN5) for endothelial cells (Figure 9c, Appendix Figure 3, Supplementary Table 2, 
Appendix I, Methods). Combining control and CTE subjects, we identified a total of 
18,491 OLs (~75%), 2,598 astrocytes (~11%), 1,879 OPCs (~8%), 596 microglia (~2%), 
857 excitatory neurons (~3%), 271 interneurons (~1%), and 43 endothelial cells (~0.2%). 
This cell type distribution is similar to what has been previously observed in human white 
matter tissue116. 
Examination of the tSNE projection anchored with cell-identity markers 
suggested multiple differences in CTE as compared to control samples when split by 
condition (Figure 9b, middle), including fewer OLs, an increase in the number of disease-
specific OL subpopulations, and a shift in the expected astrocyte subpopulation 
heterogeneity. To determine whether these observed differences between CTE and 
control tissue partially reflected subject-specific variation rather than condition, we 
normalized nuclei numbers to the subject with the highest number of nuclei (see methods 
in118, Appendix I, Methods) and compared the distributions of total nuclei in each cluster 






of nuclei comprising each cluster, we nonetheless were able to identify statistically 
significant differences between CTE and control after normalization (Figure 9d, 
Appendix I, Methods). Specifically, we observed the presence of OL subpopulations that 
were significantly elevated in CTE, which may suggest a disease-specific OL 
population116,124. 
We also conducted bulk gene expression analysis to determine if we could 
identify a more general disease-specific gene expression signature. Bulk gene expression 
revealed several genes previously implicated in neurodegeneration. We identified a 
greater abundance of transcripts encoding dipeptidyl peptidase 10 (DPP10), a voltage-
gated potassium channel protein positively associated with p-tau-positive neurofibrillary 
tangles192; clusterin (CLU), a glycoprotein positively associated with β-amyloid (Aβ) 
toxicity and cell stress193; and dystrobrevin alpha (DTNA), an astrocytic protein 
associated with dementia status and p-tau aggregation194 (Appendix Figure 4). We 
identified lower levels of transcripts encoding RING finger protein 220 (RNF220), a 
protein associated with cholesterol metabolism and neurodegeneration195 (Appendix 
Figure 4). We also identified lower levels of transcripts encoding transferrin (TF) and 
fatty acid 2-hydroxylase (FA2H), two proteins associated with iron accumulation196 and 







matter taken for snRNA-seq analysis and validation. Dounce homogenizer for  tissue disassociation. Inverted 
microscope for single-nucleus hydrogel encapsulation. Sequencer and example data. b. (left) Unbiased tSNE 
showing all major cell-types expected in human brain tissue. (middle) tSNE colored by condition, control: 
red, CTE: teal. (right) tSNE colored by subject, figure key below. c. tSNE projection of each major cell type 
colored by expression of canonical marker genes. Nuclei clusters positive for each marker gene are circled 
by a dashed line. d. Bubble plot of normalized number of nuclei with each subject in the data set on the y-
axis and each cell-type and subpopulation on the x-axis. Size of the bubble indicates the number of 
normalized nuclei in each cell-type for each subject. P-values for all nuclei subpopulations listed at top (n = 
8 per condition; Astrocyte1: U = 19.5; Astrocyte2: U = 16.5; Astrocyte3: U = 27.0; Endothelia: U = 22.5; 
Microglia: U = 22.0; Exc_Neuron1: U = 24.0; Int_Neuron: U = 21.0; Exc_Neuron2: U = 29.0; OL1: U = 6.0; 
OL2: U = 19.0; OL3: U = 27.0; OL4: U = 10.0; OL5: U = 0.0; OL6: U = 5.5; OL7: U = 11.0; OL8: U = 5.5; 
OPC1: P = 0.22, U = 16.0; OPC2: P = 0.07, U = 11.0; FDR-corrected two-tailed Mann-Whitney U test).  
Molecular Profiling Points to Fewer OLs in CTE White Matter Compared to Control 
To investigate cell-type-specific differences in OLs in CTE compared to controls, 
we isolated OL nuclei clusters from our primary tSNE projection and re-projected OL 
nuclei as a subset tSNE by identifying each nucleus previously identified as an OL and 
performing unbiased graph-based clustering to produce an OL-specific tSNE121,198 
(Figure 10a). Consistent with our primary tSNE projection, we observed fewer OLs in 
CTE compared to control and the presence of CTE-specific OL subpopulations. To assess 
whether these differences were driven by a subset of subjects, we compared normalized 
nuclei counts between CTE and controls (Figure 10b, Supplementary Table 5, Methods). 
We observed a statistically significant decrease in the number of OLs in CTE subjects 
compared to control subjects (P = 0.01, two-tailed Mann-Whitney U test). These findings 
suggest OL cell death and myelin loss, consistent with what has been found at the light 
microscopic level in CTE5,14,62,185. 
We performed IHC and smFISH to compare molecular expression in OLs in CTE 
versus control (Figure 10c-d, Appendix Figure 5). By IHC, we observed fewer OLs (as 






CTE compared to control sections, consistent with the transcriptomic findings (P = 0.04, 
one-tailed Student’s t-test) (Figure 10c, Appendix Figure 5a-b). By smFISH, we also 
observed fewer OLIG2 positive cells in CTE versus control (P = 0.02, one-tailed 
Student’s t-test) (Figure 10d, Appendix Figure 5a-b). Furthermore, we determined that 
there were fewer OLs throughout the entire subcortical white matter in CTE, and not 
restricted to the subcortical U-fiber area (Figure 10c, Appendix Figure 5a-b). Notably, we 
observed a significant, positive correlation between the number of OLs identified by 
snRNA-seq and smFISH when tracked by subject (Pearson’s r = 0.4995, P = 0.0488) 
(Figure 10e), suggesting that the normalized nuclei counts accurately reflected in situ cell 
type abundance. 
The in situ probes for OLs also identify OPCs, potentially accounting for the 
correlative variance between OL cell numbers in the different techniques. We did not 
observe differences in OPC numbers in our transcriptomic analysis (P = 0.13, two-tailed 
Mann-Whitney U test) (Appendix Figure 6a,b). Furthermore, we performed IHC against 
platelet derived growth factor receptor A (PDGFRα), an OPC marker, and found no 
detectable differences (P = 0.23, one-tailed Student’s t-test) (Appendix Figure 6c). This 








from primary tSNE from Figure 9b. b. Scatter plot with bar for normalized nuclei counts for all OL lineage 
nuclei, dot represents the total normalized number of OL lineage nuclei in one subject (n = 8 per condition, 
median of CTE = 3,331, median of control = 5,023, P = 0.01, FDR-corrected two-tailed Mann-Whitney U 
test, U = 9.0). c. Representative immunohistochemistry images (anti-OLIG2 for OL lineage cells) of control 
and CTE tissue. Scale bar (top, white): 100 µm. Quantification (bottom) for number of OLIG2-positive 
nuclei per mm2 over the entire white matter sample for each subject (n = 8 per condition, P = 0.0484, one-
tailed Student’s t-test, t(14) = 1.780). d. Representative smFISH images for OLIG2 (green) and DAPI (blue). 
Scale bar (top, white): 50 µm. Quantification (bottom) for number of OLIG2-positive nuclei for each subject 
(n = 8 per condition, P = 0.03, one-tailed Student’s t-test, t(14) = 2.103). e. Scatter plot for number of OLs 
identified by smFISH and snRNA-seq. Each dot represents one subject. Control: red, CTE: teal. (r = .4995, 
P = 0.0488, R2 = 0.25). f. Volcano plot for differentially expressed OL genes between CTE and controls 
(Bonferroni correction for multiple comparisons). Vertical dashed lines indicate log2(Fold change) cutoff of 
0.01. Horizontal dashed lines indicate -log10(adjusted P-value) cutoff of 0.05. Red dots are CTE-associated 
differentially expressed OL lineage genes (n = 316). All data was presented in Mean ± S.E.M. 
These analyses suggest that there are fewer OLs in CTE compared to control, 
supporting OL death and myelin loss. Further, they suggest a potential role for iron 
accumulation and apoptosis as contributing factors to CTE pathogenesis. 
Iron Accumulation and Markers of Cellular Stress Response Characterize a Specific OL 
Subgroup in CTE 
Having observed aberrant OL subpopulations in CTE, we examined whether these 
differences were disease specific. We first considered the contrast of fewer overall OLs to 
the apparent increases in OL cell numbers in certain subpopulation clusters in CTE 
versus controls (Figure 11a). To determine whether these OL subpopulations consistently 
harbored more cells in CTE samples, we compared normalized nuclei counts between 
CTE and control (Figure 11b, Supplementary Table 5, Appendix I, Methods). All 3 CTE-
specific OL subpopulations (OL6, OL7, and OL8) were significantly elevated in CTE 
compared to control (OL6: P = 0.001, OL7: P = 0.01, OL8: P = 0.05, two-tailed non-






To determine whether differentially expressed genes in CTE OLs were associated 
with dysregulated gene modules, we performed gene ontology (GO) analysis199 using the 
identified differentially expressed genes in OLs in CTE versus controls. GO analysis 
revealed a significant increase in gene modules related to iron, iron binding, mRNA 
translation, and ribosomal processes (Figure 11c, Supplementary Table 4).  
With the emergence of CTE-specific subpopulations in contrast with an overall 
reduction of OLs in CTE, we wondered whether the CTE-specific subpopulations may be 
driving the upregulation of gene transcripts associated with iron accumulation and 
cellular stress response. We compared the gene expression profiles of CTE-specific OL 
subclusters (OL6, OL7, and OL8) to all other OL subclusters in both CTE and control 
and identified three differentially expressed genes associated with aberrant iron 
accumulation FTH1 and cellular stress response, CRYAB, and HSP90AA1 (Figure 11d, 
Supplementary Table 3)12,200–202. We then visualized the gene expression profiles of each 
OL subpopulation individually (Appendix Figure 7, Supplementary Table 2). 
Interestingly, the most compelling upregulation of iron accumulation genes and cellular 
stress response genes occurred in the OL6 subpopulation, a subpopulation that is 
significantly elevated in CTE tissue as compared to control (Figure 11e). The OL6 
subpopulation, when compared to every other OL subcluster, expressed significantly 
more transcripts for FTH1, CRYAB, and HSP90AA1. 
To independently validate the presence of excess iron accumulation in CTE, we 
analyzed the tissue histochemically for iron aggregates (hemosiderin)12,203 (Figure 11f, 






aggregates in CTE white matter compared to control (P = 0.04, one-tailed parametric 
Student’s t-test) (Figure 11f, right). Finally, to validate the presence of OLs with 
abundant FTH1 and CRYAB transcripts, we performed multiplexed smFISH on all control 
and CTE subjects (Figure 11g, Appendix Figure 8c). Due to an overall reduced number 
of OLs in CTE tissue compared to control tissue (Figure 10), we identified sparse groups 
of OLIG2 positive nuclei in CTE (Figure 10d). OLs in CTE tissue demonstrated 
positivity for FTH1 and CRYAB, consistent the OL6 subpopulation (Figure 11g, 
Appendix Figure 8c). Together, these findings suggest that aberrant iron accumulation in 







of mature OL lineage nuclei subset from primary tSNE from Figure 9b with CTE-specific subpopulations 
circled. b. Scatter plot with bar for normalized nuclei counts for CTE-specific OL subpopulations, each dot 
represents one subject (n = 8 per condition; OL6: P = 0.001, U = 0.0; OL7: P = 0.01, U = 5.5; OL8: P = 0.05, 
U = 11.0; FDR-corrected two-tailed Mann-Whitney U test). c. Top 5 enriched gene ontology terms for OLs 
in CTE ranked by fold enrichment. d. Violin plots of log-normalized counts for top expressed genes in CTE-
specific OLs. e. Scatter plot for average gene expression in OL6. Control gene expression across the x-axis, 
CTE gene expression across the y-axis. FTH1 and CRYAB are labeled as top differentially expressed genes 
between CTE and controls. f. Representative images of Prussian blue staining for control and CTE tissue. 
Black arrows label iron inclusions. Scale bar (left, white): 100 µm. Quantification (right) for total iron 
inclusion count, each dot represents a subject (n = 8 per condition, P = 0.04, one-tailed Student’s t-test, t(14) 
= 1.878). g. Representative multiplexed smFISH images for OLIG2 (green), FTH1 (yellow), CRYAB (red), 
and DAPI (blue). OLIG2 and DAPI (left), FTH1 and DAPI (middle-left), CRYAB and DAPI (middle-right), 
and merge of all probes (right). White arrows label nuclei positive for OLIG2, FTH1, CRYAB, and DAPI. 
Scale bar (top-left, white): 50 µm. All data was presented in Mean ± S.E.M. 
Identification of Neuroinflammatory Astrocytes in CTE White Matter 
The transcriptomic data also pointed to alterations in the heterogeneity of 
astrocytes, albeit without changing the overall cell number (Appendix Figure 9a). In 
many neurological diseases, the total number of astrocytes is increased and “reactive” 
astrocytes predominate118,204–206. However, we did not see a difference in the total number 
of astrocytes in CTE compared to control5 (P = 0.29, two-tailed Mann-Whitney U test) 
(Appendix Figure 9b). We confirmed this finding by IHC and smFISH (P = 0.44 and P = 
0.50, respectively; one-tailed Mann Whitney U-test, FDR-corrected) (Appendix Figure 
9c-d). 
We re-projected each astrocyte nucleus data point as a subset tSNE from the 
primary tSNE as described above for OLs (Figure 12a). We observed two CTE-specific 
astrocyte subpopulations, designated Astrocyte2 and Astrocyte3 (Figure 12a). We found 
a significant decrease in the number of normalized Astrocyte1 nuclei and a significant 
increase in the number of normalized Astrocyte2 and Astrocyte3 nuclei in CTE as 
compared to controls (Astrocyte1: P = 0.02, Astrocyte2: P = 0.01, Astrocyte3: P = 0.03, 






Methods). To reveal the transcripts driving the emergence of each subpopulation, we 
performed cell-type marker analysis (Supplementary Table 2). The Astrocyte1 group 
expressed many genes associated with normal functioning astrocytes (e.g. GFAP, catenin 
delta-2 (CTNND2), aquaporin-4 (AQP4)), while the Astrocyte2 group expressed 
transcripts genes associated with dysfunctional metabolism (e.g. pyruvate dehydrogenase 
kinase 4 (PDK4)207), and the Astrocyte3 group showed enrichment for transcripts 
associated with neuroinflammation and aging (cluster of differentiation 44 (CD44), B-
cell lymphoma 6 (BCL6), and alpha 1-antichymoptrypsin (SERPINA3)118,205) (Figure 12c, 
Supplementary Table 3). Additional gene expression analysis for the Astrocyte3 group 
transcript profile confirmed increases in mRNAs related to neuroinflammation, 
suggesting that Astrocyte3 may represent a CTE-specific astrocyte subpopulation and/or 







subpopulations, each dot represents one subject (n = 8 per condition; Astrocyte1: P = 0.02, U = 2.0; 
Astrocyte2: P = 0.01, U = 7.5; Astrocyte3: P = 0.03, U = 12.0; FDR-corrected two-tailed Mann-Whitney U 
test). c. Violin plots of log-normalized counts for top expressed genes in CTE-specific astrocytes. d. Volcano 
plot for differentially expressed Astrocyte3 genes between CTE and controls (Bonferroni correction for 
multiple comparisons). Vertical dashed lines indicate log2(Fold change) cutoff of 0.01. Horizontal dashed 
lines indicate -log10(adjusted P-value) cutoff of 0.05. Red dots are CTE-associated differentially expressed 
Astrocyte3 genes that pass both cutoffs. n = 105 differentially expressed genes. e. Representative IF images 
for GFAP (teal), CD44 (yellow), and DAPI (blue) in control and CTE. Scale bar (left, white): 100 µm. 
Quantification (right) for percent of total area positive for CD44 IF for each subject (P = 0.02, one-tailed 
Student’s t-test). f. Representative multiplexed smFISH images for GFAP (teal), CD44 (yellow), BCL6 (red), 
and DAPI (blue). GFAP and DAPI (left), CD44 and DAPI (middle-left), BCL6 and DAPI (middle-right), 
and merge of all probes (right). White arrows label nuclei positive for GFAP, CD44, BCL6, and DAPI. Scale 
bar (top-left, white): 50 µm. g. Top 10 enriched gene ontology terms for astrocytes in CTE ranked by FDR. 
All data was presented in Mean ± S.E.M. 
To validate finding more astrocytes with enriched levels of CD44 transcripts in 
CTE compared to control, we assessed in situ CD44 protein by IF, co-staining with the 
astrocyte marker GFAP (Figure 12e, Appendix Figure 10a). We observed a significant 
increase in total area of CD44 immunopositivity in CTE compared to control (P = 0.02, 
one-tailed Student’s t-test) (Figure 12e, right), consistent with an increase in the number 
of astrocytes expressing CD44 and an increase in the Astrocyte3 cluster. There was no 
significant change in the overall area of GFAP immunopositivity between CTE and 
controls (P = 0.44, one-tailed parametric Student’s t-test) (Appendix Figure 9c, Appendix 
Figure 10a), indicating no quantifiable morphologic change in CTE to astrocytes in the 
context of indistinguishable numbers of astrocytes between CTE and control by 
normalized nuclei counts (P = 0.29, two-tailed non-parametric Mann-Whitney U test) 
(Appendix Figure 9a,b) and by smFISH (P = 0.50, one-tailed non-parametric Mann 
Whitney U-test) (Appendix Figure 9d). Further, we found transcript profiles, by 
multiplexed smFISH, consistent with the Astrocyte3 cluster in CTE (CD44 and BCL6) 






We also performed gene ontology (GO) analysis199 using the identified 
differentially expressed genes in astrocytes in CTE versus controls. We found a 
significant increase in transcripts related to processes such as protein folding, heat 
response, and regulation of apoptosis, which are often observed in disease-associated 
astrocytes205 (Figure 12g, Supplementary Table 4). 
Together, these findings suggest that the overall number of astrocytes in CTE 
white matter is unchanged compared to controls, but there is a shift to greater astrocyte 
subpopulations demonstrating neuroinflammatory and dysfunctional metabolic states. 
These findings support the possibility that astrocytes in CTE alter their genetic profiles to 
become neuroinflammatory. 
Differential Gene Expression in Neurons, OPCs, and Microglia 
Differentially expressed genes between CTE and controls were detected for every 
cell type captured in our snRNA-seq analysis with the exception of endothelial cells 
(Supplementary Table 3). No differentially expressed genes were detected between CTE 
and control endothelial cells, likely due to limited numbers (n = 43 for CTE and control 
nuclei combined). OPCs contained only one differentially expressed gene. In OPCs, 
enrichment of human leukocyte antigen A (HLA-A), was detected in CTE OPCs compared 
to controls (Supplementary Table 3). Upregulation of HLA system proteins, including 
HLA-A, are implicated in demyelinating diseases like multiple sclerosis and multiple 






microglia, presented with gene expression differences related to neurodegeneration, iron 
dysregulation, and traumatic brain injury (TBI). 
Excitatory neurons in CTE displayed increased catenin alpha 2 (CTNNA2) 
compared to controls, an overexpression of which is associated with reduced dendritic 
spine loss210 (Supplementary Table 3). With frontal lobe dendritic spine number and 
density reduced in CTE211, increased transcripts of CTNNA2 may indicate a compensatory 
measure in white matter excitatory neurons. Calcium-binding protein 1 (CABP1), which 
negatively regulates a calcium channel protein implicated in neurodegenerative disease-
related neuronal calcium dyshomeostasis, was also increased in CTE compared to control 
excitatory neurons (Supplementary Table 3)212,213. Differential gene expression analysis 
revealed enrichment of a single gene, DPP10, in CTE interneurons compared to control.  
Further findings related to iron trafficking and iron oversaturation were present 
within other glial cell types in the dataset. In microglia, we detected reduced transcripts in 
CTE compared to controls of both TF and FA2H (Supplementary Table 3)197. Reduced 
levels of TF were also detected in CTE astrocytes compared to controls (Supplementary 
Table 3).  
Discussion 
To advance understanding of the brain abnormalities associated with CTE, we 
explored an understudied yet likely relevant brain region–the white matter at the depth of 
the dorsolateral frontal sulcus2,5–using techniques offering molecular and cellular 
resolution. Specifically, we performed a comparative transcriptomic analysis of 






neuropathologically-verified CTE, a progressive neurodegenerative disease associated 
with behavioral, mood, and cognitive symptoms2,5,47,64. CTE is defined 
neuropathologically by a distinctive pattern of p-tau accumulations in the cortical gray 
matter, often most severe in the dorsolateral frontal sulcus2,5. The white matter underlying 
the dorsolateral frontal sulcus shows white matter rarefaction, myelin and axonal loss, 
astrocytic degeneration, and often, hemosiderin-laden macrophages5,6,59,62. We report 
analyses of 24,735 cell nuclei isolated across 16 male subjects, 8 with 
neuropathologically verified CTE and 8 age- and PMI-matched controls. By performing 
snRNA-seq transcriptomic analysis in the white matter at the depth of the dorsolateral 
frontal sulcus, the present study revealed fewer OLs in CTE compared to controls and 
differences within the oligodendroglial and astrocyte subpopulations. The 
transcriptomically unique profiles distinguishing OL subtypes and/or OL cell states in 
CTE point to an enrichment of cellular phenotypes involving cell stress response 
programs and iron accumulation pathways (CRYAB200 and FTH112,201 transcripts, 
respectively). With respect to astrocytes, transcriptomic analyses suggest enrichment of 
cell subtypes and/or states associated with neuroinflammation and dysfunctional 
metabolism, without a change in overall astrocyte number. 
Previous snRNA-seq analyses in both TBI and another neurodegenerative 
tauopathy, Alzheimer’s disease (AD), have also identified OL abnormalities. Mice have 
reduced numbers of hippocampal OLs and an upregulation of Tf in all OLs as an acute 
response to traumatic brain injury (TBI)214,215. Upregulation of Tf in murine OLs is likely 






OLs216. Myelination-related transcriptional changes have been identified in previous 
transcriptomic analyses of cerebral cortex gray matter in postmortem AD. Regulators of 
myelination (leucine rich repeat and Ig domain containing 1 (LINGO1)) have widespread 
abnormalities in expression across neuronal and glial cell types in AD122. Cortical OLs in 
AD express fewer transcripts associated with myelination, axonal guidance, 
cytoskeleture, and maturation of myelin (semaphorin-3B (SEMA3B), microRNA 219a-2 
(MIR219A2), and stathmin 4 (STMN4)125. These previous snRNA-seq findings, in 
combination with our analyses, implicate OLs in both neurodegenerative disease 
processes and in response to TBI.  
The presented datasets serve as a mineable resource for understanding the 
molecular and cellular dysregulation associated with CTE pathogenesis. Integration with 
additional data sets is readily feasible, enabling expansion–breadth and depth–of CTE 
transcriptomic profiles, further informing potential mechanisms of CTE pathogenesis. 
Elucidating the mechanism by which excessive iron accumulation links to OL cell death 
is also an active area of pursuit experimentally, as is delineating the role of 
neuroinflammatory astrocytes in disease progression. The present findings and the future 
experiments they stimulate are expected to inform the central goals of the field, which is 
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Abstract 
Alzheimer’s disease (AD) is the most common progressive tauopathy and 
neurodegenerative disease, typically affecting adults over the age of 65. White matter 
atrophy and axonal loss have been reported histologically in AD but have yet to be well 
characterized on a molecular or cellular level. Here, we present RNA sequencing profiles 
of postmortem dorsolateral frontal white matter cell nuclei from four individuals with 
neuropathologically confirmed AD and eight age-, sex-, and RNA integrity number-
matched controls. We identified sixteen transcriptomically distinct cell groups, reflecting 
cell types and/or states, through unbiased clustering approaches. As well, we identified 
cell group-specific differences between AD versus control tissue, which were validated 
by single-molecule fluorescent mRNA in situ hybridization on adjacent tissue sections. 






which were increased in number overall and showed an enrichment for transcripts 
relevant to neuroinflammation and aging. Oligodendrocytes (OLs) were diminished in 
number overall but did not show enrichment for any disease-specific transcripts. A subset 
of microglia was increased in number and morphologically distinct in situ, which may 
suggest activation of disease-associated microglia. These results demonstrate specific 
molecular and cellular alterations in astrocytes, OLs, and microglia associated with AD, 
and may provide potential targets for future therapeutic interventions. 
Introduction 
Alzheimer’s disease (AD) is the most common neurodegenerative disease. 
Primary symptoms of AD include of progressive memory loss, marked cognitive 
impairment, executive dysfunction, mood alterations, behavioral abnormalities, language 
dysfunction, and dementia102. AD is characterized neuropathologically by β-amyloid 
(Aβ) neuritic plaques and neurofibrillary tangles (NFTs) primarily in the limbic system 
and the medial temporal and frontal lobes of the brain3. The distinctive Aβ and p-tau 
pathology of AD primarily involves the medial temporal lobe, limbic structures, and gray 
matter throughout much of the brain3. To date, reports have largely focused on general 
characteristics of AD pathogenesis, postmortem diagnostic criteria, and molecular 
changes in the gray matter. Fewer studies have explored alterations at the molecular and 
cellular levels in the white matter, a primary goal of the present study. We sought to 
describe cell-type-specific transcriptomic profiles of cell nuclei in white matter of 






controls by using single-nucleus RNA-seq (snRNA-seq), previously used by Mathys et 
al. and Grubman et al. to explore the cortical gray matter of AD121,122.  
Results 
Single-Nucleus RNA Sequencing of Human Alzheimer’s Disease White Matter 
To understand the molecular and cellular profiles of white matter in individuals 
diagnosed postmortem with AD, brain tissue from Brodmann Area 8/9 (BA8/9) was 
collected from 4 male individuals neuropathologically diagnosed with AD Braak VI 
(late-stage) and 8 age-matched male individuals with no AD or neurological comorbidity 
(Figure 13a, Appendix Figure 2a-d). Clinical demographics and neuropathological 
diagnoses are provided in Appendix Table 4. BA8/9 was selected as it is an area of severe 
p-tau pathology in late-stage AD21. We selected subjects diagnosed neuropathologically 
with Braak VI AD in accordance with the National Institute on Aging—Alzheimer’s 
Association (NIAA) criteria for AD and Braak staging3,21,97. All subjects with AD had no 
other co-morbid neurodegenerative disease, such as chronic traumatic encephalopathy 
(CTE), Lewy body disease or frontotemporal lobar degeneration. However, all subjects 
experienced some degree of repetitive head injury (RHI) exposure. We performed a 
snRNA-seq transcriptomic analysis to reveal cell-type-specific differences between 
subjects with neuropathologically confirmed AD and age-matched controls. We report a 
total of 20,466 droplet-based snRNA-seq profiles across 12 subjects with a median of 567 
genes and 846 unique molecular identifiers (UMIs) per nucleus (Figure 13, Appendix 







Figure 13. Overview of snRNA-seq and experimental approach. a. (far left) Illustration of dorsolateral 
frontal white matter and white matter at the depth of a cortical sulcus taken for snRNA-seq analysis and in 
situ validation analyses. (middle left) Dounce homogenizer used to dissociate tissue. Inverted microscope 






example data produced by the snRNA-seq workflow. b. (left) Unbiased tSNE projection showing all major 
cell-types expected in human brain tissue. (middle) tSNE colored by condition, control: red, AD: teal. (right) 
tSNE colored by subject. Each subject is a different color, as shown by the figure key on right. c. tSNE 
projection of each major cell type colored by expression of canonical marker genes: PLP1 for OLs, GFAP 
for astrocytes, VCAN for OPCs, CD74 for microglia, SYT1 for neurons. Nuclei clusters positive for each 
marker gene are circled by a dashed line. d. Bubble plot of normalized number of nuclei with each subject in 
the data set on the y-axis and each cell-type on the x-axis. Size of the bubble indicates the number of 
normalized nuclei in each cell-type for each subject. Statistical analysis for significantly increased or 
decreased nuclei subpopulations listed at top (n = 8 (Control), n = 4 (AD); Astrocytes: P = 0.03, U = 3.0; 
Endothelial cells: P = 0.05, U = 4.5; Microglia: P = 0.46, U = 11.0; OLs: P = 0.0485, U = 4.0; Neurons: P = 
0.21, U = 8.0; OPCs: P = 0.11, U = 6.0; FDR-corrected two-tailed Mann-Whitney U test). e. Volcano plot 
for  all differentially expressed genes between AD and control. Log2(Fold change) on the x-axis and -
log10(adjusted P-value) on the y-axis. P-value adjusted by Bonferroni correction for multiple comparisons. 
Vertical dashed lines indicate log2(Fold change) cutoff of 0.01. Horizontal dashed lines indicate -
log10(adjusted P-value) cutoff of 0.05. Red dots are AD-associated differentially expressed genes that pass 
both cutoffs. 
Cellular Diversity and Cell-type-specific Differences between AD and Control White 
Matter 
For transcriptomic analyses, we collected intact nuclei by mechanical and 
enzymatic dissociation and density gradient ultracentrifugation from 1-cm3 frozen tissue 
blocks of BA8/9 (Appendix I, Methods). We collected the white matter immediately 
beneath the cortical ribbon at the depth of the sulcus in order to target the subcortical U-
fibers, a specific tissue area in which myelin thinning, associated with reduced cognitive 
functioning even in early AD, has been reported110 (Figure 13a, Appendix Figure 2a). For 
in situ validations, we collected frozen tissue sections from BA8/9 containing both 
cortical and white matter tissue from the area directly adjacent to the block taken for 
snRNA-seq transcriptomic analysis (Appendix Figure 2a). 
After collecting cell nuclei, we used the inDrops method to encapsulate nuclei in 
hydrogel droplets, reverse transcribe mRNA to cDNA, and tag each cDNA molecule with 
a cellular barcode and UMI for single cell sequencing111,115. Following sequencing, we 






nucleus transcriptomic profiles of 12 control and AD subjects (Figure 13a,b, 
Supplementary Table 9). We performed a variety of quality-control measures to identify 
high-quality cellular barcodes (nuclei) for further analysis (Appendix I, Methods). To 
identify cell-types in the data set, we constructed an unbiased k-nearest neighbor graph 
based on top principal components followed by a Jaccard similarity step and the Louvain 
modularity optimization algorithm217 to group the nuclei into clusters by gene expression 
similarities and produce a two-dimensional t-distributed stochastic neighbor embedding 
(tSNE) projection, and we identified an integrated tSNE projection with 16 
transcriptionally distinct nuclei clusters derived from control and AD samples190,218 
(Figure 13b, left, Appendix Figure 2h).  
When we separated the tSNE as a control-only plot and AD-only plot, we 
observed several differences in cluster structure, indicative of cell-type specific 
alterations (Figure 13b, middle). To identify cell types, we labeled clusters of nuclei by 
expression of canonical cell type marker: proteolipid protein 1 (PLP1) for 
oligodendrocytes (OLs), glial fibrillary acidic protein (GFAP) for astrocytes, versican 
(VCAN) for oligodendrocyte precursor cells (OPCs), cluster of differentiation 74 (CD74) 
for microglia, synaptotagmin-1 (SYT1) for neurons, claudin-5 (CLDN5) for endothelial 
cells116–118,121,122 (Figure 13c, Supplementary Table 9, Supplementary Table 10, Appendix 
I, Methods). Combining control and AD subjects, we identified a total of 16,085 OLs 
(~79%), 2,085 astrocytes (~10%), 1,386 OPCs (~7%), 541 neurons ( ~3%), 335 microglia 
(~2%), and 34 endothelial cells (~0.2%). The cellular population demographics are 






Upon generation of a tSNE projection with optimal input parameters and labeled 
by cell-type marker genes, we identified fewer OLs in AD, an increase in the number of 
astrocytes in AD, and a shift in the expected microglia subpopulation heterogeneity in 
AD. To determine whether observed differences between AD and control tissue were the 
result of subject-specific variation, we normalized nuclei numbers to the subject with the 
highest number of nuclei (see methods in118, Appendix I, Methods) and compared the 
distributions of total nuclei in each cluster by subject (Figure 13d). We identified 
significant differences between AD and control (Figure 13b). Specifically, we observed a 
significant decrease in the number of OLs and a significant increase in the number of 
astrocytes in AD compared to control (Figure 14b, Figure 15b). Bulk gene expression 
comparison between AD and controls additionally revealed several gene expression 
differences previously implicated in neurodegeneration. We identified an upregulation of 
dipeptidyl peptidase like 10 (DPP10; encodes a voltage-gated potassium channel protein 
positively associated with p-tau-positive neurofibrillary tangles192), an upregulation of 
crystallin alpha b (CRYAB; encodes a neuroprotective, anti-apoptotic factor200,219), and an 
upregulation of GFAP, whose protein is considered a marker of neuroinflammatory 
astrogliosis in neurological diseases when upregulated220 (Figure 13e).  
Fewer OLs in AD White Matter Compared to Control 
  To further investigate the cell-type-specific differences associated with OLs in 
AD, we isolated OL nuclei clusters from our primary tSNE projection and re-projected 






that was previously identified as an OL. We isolated the OL nuclei and performed 
unbiased graph-based clustering steps to produce an OL-specific tSNE. This allows for a 
higher resolution comparison between AD and controls by removing all non-OL cell 
types and focusing the comparison on OLs alone. Consistent with our primary tSNE 
projection, we observed fewer OLs in AD compared to controls (Figure 14b). To address 
whether these differences were driven by a subset of subjects, we compared normalized 
nuclei counts between AD and controls (Figure 14b, Supplementary Table 12, Methods). 
We observed a significant decrease in the number of OLs in AD subjects, compared to 
control subjects (P = 0.0485, two-tailed Mann-Whitney U test) (Figure 14b). These 
findings suggest potential OL cell death and potential myelin loss.  
We did not detect a reduced number of oligodendrocyte transcription factor 2 
protein- (OLIG2-) positive cells in AD compared to controls by immunohistochemistry 
(IHC) (P = 0.36, one-tailed Student’s t-test) (Figure 14d, Appendix Figure 12a,b). 
However this discrepancy could be explained by our observation that AD white matter 
contained significantly more platelet-derived growth factor receptor A- (PDGFRα-) 
positive OPCs (P = 0.02, one-tailed Student’s t-test), which are also positive for OLIG2 
(Figure 14e, Appendix Figure 12c,d). 
To further understand the gene expression that might be driving the observed 
lower OL abundance in AD, we tested for differential gene expression between AD and 
control. The most differentially expressed genes between AD and controls included 
CRYAB, metallothionein 3 (MT3; a gene involved in cellular stress response and anti-






(HSP90AA1; encoding a heat-shock protein and molecular chaperone previously 
implicated in AD disease mechanisms221–223) (Figure 14c, Supplementary Table 11). Our 
analyses demonstrate that there are fewer OLs in AD compared to controls. These 
findings support OL death and myelin loss in AD and suggest a potential role for cellular 







(n = 8 (Control), n = 4 (AD), median of Control = 5,024, median of AD = 3,241, P = 0.0485, FDR-corrected 
two-tailed Mann-Whitney U test, U = 4.0). c. Volcano plot for differentially expressed OL genes between 
AD and control. Log2(Fold change) on the x-axis and -log10(adjusted P-value) on the y-axis. P-value 
adjusted by Bonferroni correction for multiple comparisons. Vertical dashed lines indicate log2(Fold change) 
cutoff of 0.01. Horizontal dashed lines indicate -log10(adjusted P-value) cutoff of 0.05. Red dots are AD-
associated differentially expressed OL lineage genes that pass both cutoffs. d. Representative IHC images 
for control and AD stained with anti-OLIG2 for OL lineage cells. Scale bar (top-left, white): 100 µm. 
Quantification (right) for the number of OLIG2+ nuclei (n = 8 (Control), n = 4 (AD), P = 0.36, one-tailed 
Student’s t-test, t(10) = 0.3749). e. Representative IHC images for control and AD stained with anti-PDGFRα 
for OPCs. Scale bar (top-left, white): 100 µm. Quantification (right) for the number of PDGFRα+ cells (n 
= 8 (Control), n = 4 (AD), P = 0.02, one-tailed Student’s t-test, t(10) = 2.143). All data was presented in 
Mean ± S.E.M.  
Increased Astrocyte Number and Identification of Neuroinflammatory Astrocytes in AD 
White Matter 
We re-projected astrocytes to produce an astrocyte-specific tSNE, allowing for a 
higher resolution comparison (Figure 15a). Consistent with what we observed in the 
primary tSNE, we identified a difference in the number of astrocytes in AD compared to 
controls. To determine whether this observation was significant, we compared 
normalized nuclei counts between AD and controls (Figure 15b). We observed a 
significant increase in the total number of astrocytes in AD compared to controls (P = 
0.03, two-tailed Mann-Whitney U test). We visualized astrocytes using 
immunofluorescence (IF) and observed a similar increase in the total number of cells 
positive for GFAP qualitatively (Figure 15g, Appendix Figure 13c). We performed 
differential gene expression analysis between AD-specific subclusters and control-
specific subclusters of astrocytes (Figure 14a), and we identified an upregulation of 
cluster of differentiation molecule 44 (CD44) and B-cell lymphoma 6 (BCL6), two genes 
associated with neuroinflammatory astrogliosis205,206 (Figure 15c). By single-molecule 






positive, and BCL6-positive nuclei in AD tissue (Figure 15e, Appendix Figure 13a,b) and 
a significantly greater number of GFAP-positive, CD44-positive nuclei in AD compared 
to controls (P = 0.002, one-tailed Student’s t-test) (Figure 15f) Additional gene 
expression analysis further revealed HSP90AA1221 and CRYAB219 as two genes previously 
associated with astrogliosis in AD (Figure 15d).  
Together, these analyses demonstrate that there are more total astrocytes in AD 
white matter compared to control, and the astrocytes in AD express genes associated with 
neuroinflammatory astrogliosis. These findings support the possibility that astrocytes in 








differentially expressed astrocyte genes between AD and control. Log2(Fold change) on the x-axis and -
log10(adjusted P-value) on the y-axis. P-value adjusted by Bonferroni correction for multiple comparisons. 
Vertical dashed lines indicate log2(Fold change) cutoff of 0.01. Horizontal dashed lines indicate -
log10(adjusted P-value) cutoff of 0.05. Red dots are AD-associated differentially expressed astrocyte genes 
that pass both cutoffs. e. Representative smFISH images for GFAP (teal), CD44 (yellow), BCL6 (red), and 
DAPI (blue). Scale bar (left, white): 50 µm. White arrow indicates GFAP+, CD44+, BCL6+, and DAPI+ 
cells. f. Quantification (right) for the number of GFAP+, CD44+ nuclei (n = 8 (Control), n = 4 (AD), P = 
0.002, one-tailed Student’s t-test, t(10) = 3.596). f. Representative IF images for GFAP (teal) and DAPI 
(blue). Scale bar (left, white): 100 µm. All data was presented in Mean ± S.E.M. 
Altered Microglia States in AD White Matter 
Finally, we investigated the role of microglia in AD white matter. To do this, we 
re-projected microglia from the primary tSNE, which resulted in a microglia-specific 
tSNE (Figure 16a). We noticed a clear altered heterogeneity in microglia states, with 
greater number of nuclei subset as Microglia1 in controls and greater numbers of 
Microglia2 subset nuclei in AD (Figure 16a,b). To determine whether these differences 
were statistically significant, we compared normalized nuclei numbers between AD and 
controls. We found significantly more of Microglia1 in controls and significantly more of 
Microglia2 in AD (P = 0.002 and P = 0.002, respectively; two-tailed Mann Whitney U 
test) (Figure 16b).  
Using differential gene expression analysis between microglia in AD and controls 
(Figure 16e,f), we identified two genes with especially high fold change. Plexin domain 
containing 2 (PLXDC2), which has been identified as significantly upregulated in late-
stage AD cortex and in microglia of an AD mouse model by bulk RNA-seq224, was the 
second most altered in fold change. FERM domain containing 4A (FRMD4A), which has 
been previously implicated as risk factor for developing AD225, had the highest fold 
change difference. Upregulation of PLXDC2 gene expression has been associated with 






associated with increased p-tau production and release, a defining feature of AD227,228. 
Additional gene expression analysis revealed an upregulation of two other genes of 
interest: CUGBP elav-like family member 2 (CELF2)229 and carbohydrate 









white): 100 µm. d. Quantification (left) for number of IBA1-positive cells per µm2 over the entire white 
matter sample for each subject (n = 8 (Control), n = 4 (AD), median of Control = 0.00006, median of AD = 
0.000116, P = 0.004, one-tailed Mann Whitney U-test, U = 1.0). Quantification (right) for the overall area 
of IBA1-positive microglial processes over the entire white matter sample for each subject (n = 8 (Control), 
n = 4 (AD), median of Control = 0.01098, median of AD = 0.01905, P = 0.008, one-tailed Mann Whitney 
U-test, U = 2). e. Violin plots of log-normalized counts for the two genes with the highest fold change in AD-
specific microglia. f. Volcano plot for differentially expressed Microglia2 genes between AD and control. 
Log2(Fold change) on the x-axis and -log10(adjusted P-value) on the y-axis. P-value adjusted by Bonferroni 
correction for multiple comparisons. Vertical dashed lines indicate log2(Fold change) cutoff of 0.01. 
Horizontal dashed lines indicate -log10(adjusted P-value) cutoff of 0.05. Red dots are AD-associated 
differentially expressed Microglia2 genes that pass both cutoffs. All data was presented in Mean ± S.E.M. 
By IHC, we detected a higher number of ionized calcium-binding adapter 
molecule 1- (IBA1-) positive microglia (P = 0.004, one-tailed Mann Whitney U-test ) and 
an increased total area of microglial processes (P = 0.008, one-tailed Mann Whitney U-
test) in AD white matter compared to controls (Figure 16c,d, Appendix Figure 14a,b). 
These combined findings suggest that the Microglia2 group identified through snRNA-
seq analysis presents with an activated microglial phenotype both transcriptionally and in 
situ. These analyses demonstrate that there is microglial activation in AD white matter.   
Discussion 
We performed a transcriptomic analysis of the dorsolateral frontal white matter 
from individuals with AD, a progressive neurodegenerative disease of aging associated 
with an array of behavioral, mood, and cognitive symptoms102. The classic presentation 
of AD includes Aβ aggregates and NFTs in the neurons and extracellular space of the 
cortical gray matter. These damaged proteins spread and result in both cortical and white 
matter atrophy. We report a total of 20,466 nuclei across 12 male subjects: 4 with 
neuropathologically diagnosed Braak VI AD and 8 age- and RNA integrity number-






Through snRNA-seq analysis, AD tissue contained fewer OLs than control, 
similar to CTE (Figure 10a-d, Figure 14a,b,d). OLs in AD differentially expressed 
transcripts primarily related to cell stress (CRYAB and MT3) and known Aβ toxicity or 
known affected genes in AD (CLU and HSP90AA1) (Figure 11c,d,f, Figure 14c). 
Astrocytes in AD expressed neuroinflammatory transcripts (CD44 and BCL6), previously 
identified as markers of reactivity (Figure 12c-e,f, Figure 15c-f)206. OPCs and microglia 
were increased in number when compared to controls (Figure 15a,b,g, Figure 14e, 
Appendix Figure 9a-d, Figure 16a-f). Microglia were found to express transcripts 
associated with activation (PLXDC2, CHST11) and known affected genes in AD 
associated with p-tau release (FRMD4A) (Figure 16a-f). Independent in situ methods 
applied on tissue sections adjacent to that used in the single-nucleus RNA-seq work 
revealed greater numbers of total astrocytes (Figure 15g), increased numbers of CD44+, 
BCL6+ astrocytes (Astrocyte3; Figure 15e), and no difference in OL number, which 
might be accounted for by increased numbers of OPCs both computationally and in situ 
(Figure 14d,e). Furthermore, AD microglia were increased in number and in process area 
compared to both controls further suggesting an activated microglia phenotype in AD 
white matter (Figure 16a-d). Together, these findings may support a cortical, Aβ/p-tau 
pathology related etiology for white matter changes in AD.  
White matter changes in AD may be driven by cortical cell death and toxicity. In 
AD, white matter integrity has been found to be directly influenced by cortical p-tau 
pathology of adjacent tissue areas in vivo105–107. Similar increases of OPCs as observed in 






attempt to remyelinate after OL cell death. Fragments of Aβ, which have been detected in 
AD white matter37 even though white matter senile plaques are rare108, have shown toxic 
effects on oligodendrocyte lineage cells and cause widespread OL cell death232,233. 
Additionally, oxidative stress and glutamatergic excitotoxicity are known factors in AD 
progression which damage OL lineage cells108,232. Together, these findings reveal 
downstream white matter effects of what has been shown previously in the cortical gray 







CHAPTER V – DISCUSSION 
Summary of Findings and Future Directions 
Parts of this section were adapted from an article in review and a manuscript in 
preparation. 
Citation and author contributions are the same as listed in Chapter II and Chapter III. 
 
Chapter II: White Matter Alterations in Brodmann Area 25 are Associated with 
Depressed Mood in Chronic Traumatic Encephalopathy 
Of the many symptoms of CTE, depression is commonly reported. However, to 
date the neuropathological correlates of these symptoms have not been focally 
investigated. In Chapter II, postmortem brain tissue from depressed mood (n = 31) and 
non-depressed mood (n = 11) subjects with CTE compared to depressed mood repetitive 
head impact- (RHI-) experienced controls (n = 13) was examined for glial, myelin 
density, and inflammatory alterations (Appendix Table 1, Appendix Table 2). This study 
was conducted using samples from the white matter of Brodmann Area 25 (BA25) in the 
anterior cingulate cortex (ACC), a brain area previously associated with emotional 
modulation, depression, and suicide, and is affected by antidepressant medication. 
Behavioral implications of BA25 changes are documented in RHI. The decreased 
fractional anisotropy of uncinate fasciculus, a white matter tract which comprises part of 
BA2584, has been found to have an association with increased self-reported depression 
symptoms in former American football players in vivo40.  
Glial, myelination and inflammation-related alterations were detected in BA25 in 






well as non-pathological controls. Within a CTE comparison, subjects with depressed 
mood contained a higher number of infiltrating cytotoxic T-cells and less myelin density 
than CTE subjects without depressed mood. Significantly increased numbers and overall 
area of microglia and their processes were observed in depressed mood CTE compared to 
both pooled controls and compared to non-depressed mood controls.  
Limitations of this study include a lack of assessment of individual myelinated 
fibers at high resolution, focusing instead on overall myelination at a lower resolution, as 
well as limited sample size. These preliminary results would benefit from validation in 
additional studies with larger cohorts and non-RHI exposed controls. Furthermore, 
stratification of RHI-exposed controls by depression status was completed, but due to the 
low numbers of control subjects in this study the comparison was underpowered 
(Appendix Table 2). Due to the extended fixation time of many of the biological samples 
used in this study, attempts to use antibodies against oligodendrocyte (OL) lineage cells 
and Prussian Blue staining for iron were unsuccessful.  
Future studies examining white matter fiber integrity using electron microscopy 
or Coherent anti-Stokes Raman spectroscopy, as well as the identification of OL lineage 
cells, would help clarify white matter alterations in CTE and CTE-associated symptoms. 
Quantification of other white matter- and psychiatrically relevant proteins, such as 
neuregulin-1 (NRG1) or ErbB382-85, is also merited. Cellular reconstructions to determine 
morphological features of glial cells, as previously implicated in depression and suicide24, 
25, 86, may help to determine their relevance in CTE-related depression. Finally, the 






alterations including explosivity, impulsivity, and aggression, remain to be examined in 
focused neurobiological studies2. 
Chapter III: Altered Oligodendroglia and Astroglia in Chronic Traumatic 
Encephalopathy 
In Chapter III, dorsolateral frontal white matter cell nuclei from subjects with 
neuropathologically confirmed McKee Stage II or III CTE (n = 8) and sex-, age-, 
postmortem interval- (PMI-), and RIN-matched controls (n = 8) were sequenced through 
a single-nucleus RNA-seq (snRNA-seq) pipeline (Figure 4, Appendix Figure 1a-d). CTE 
samples were found to contain lower numbers of OLs compared to controls and several 
sub-clusters of CTE-specific transcriptional profiles were identified (FTH1-positive, 
CRYAB-positive OLs and CD44-positive, BCL6-positive astrocytes). Independent in situ 
methods applied on tissue sections adjacent to that used in the snRNA-seq analysis 
yielded similar findings. We determined that there were more iron inclusions in CTE than 
control, possibly linked to the iron trafficking related transcriptional upregulations 
discovered in CTE-specific OLs. These results suggest that the BBB, the source of free 
iron in the brain, may contribute to white matter pathology in CTE beyond what was 
previously known. 
Limitations of this study include the limited number of subjects in this study, lack 
of colocalization of iron inclusions to OLs, lack of an RHI-experienced control 
comparison, vascular disease as a cause of death for some subjects, and lack of symptom 






human brain tissue have fewer or comparable numbers of subjects in their analyses, 
increasing subject number may have allowed for detecting differential gene expression 
differences and/or read depth in more cell types. Additionally, there is no definitive 
validation of iron inclusions being inside or near OLs, although the results suggest that 
OL loss may be driven by ferroptosis. The results of this chapter cannot be completely 
attributed to purely CTE pathology as there is a lack of RHI-experienced, non-
neurodegenerative controls in the study. Furthermore, cardiovascular disease may be a 
confounding variable in this study as it affects the vasculature of the brain and was the 
cause of death in several CTE cases (Appendix Table 3). However, several control 
subjects also died by cardiovascular disease and other causes related to or associated with 
vasculature damage (deep vein thrombosis, obesity, and asphyxia) (Appendix Table 3). 
Finally, although this dissertation discusses the association of the brain region analyzed 
in Chapter III to depression symptoms in CTE, clinical information was not available for 
the majority of samples and no associations can be drawn between glial cell presentation 
in Chapter III and symptoms. Samples were chosen based on best fit for snRNA-seq 
analysis (age, PMI, RIN, CTE diagnosis, no comorbid disease diagnosis, and available 
matching controls).  
Additional studies are warranted to determine whether these same changes occur 
in other brain regions, parallel the progression of p-tau pathology, or correlate with 
symptom severity in CTE. Further, a complimentary study of adjacent cortical brain 
regions would allow for a more nuanced picture of CTE pathology and white matter-






differences in CTE revealed here are also present within the frontal gray matter as well as 
in other brain regions in CTE. In addition, it will be important to ascertain whether the 
present findings are discernable after RHI prior to the earliest pathology of CTE (McKee 
Stage I) and whether they change in parallel with the progression of p-tau pathological 
severity. Correlating these changes with clinical symptom severity in CTE will also be 
important, as OL loss might produce disconnection of critical white matter circuits and 
contribute to clinical manifestations of depression in CTE. Although the cell number 
distribution presented here aligns with the only previous study examining human white 
matter using snRNA-seq116, we did not observe abundant transcriptional or cell-type 
differences associated with neurons, microglia, or endothelial cells, likely due to under 
sampling of those cell nuclei. OLs are abundant in human white matter tissue and the 
present dataset contains over seven-fold more OLs than astrocytes, the other cell type of 
interest with notable transcriptional differences between CTE and control samples. With 
known biases in snRNA-seq against capturing microglia and endothelial cells234, 
additional transcriptional investigations of these cells should be conducted in the white 
matter of CTE, especially with neuroinflammation and BBB damage as likely drivers of 
p-tau pathology235. The observed neuroinflammatory transcriptional profile of astrocytes 
in the context of increased white matter iron concentration and the presence of OLs 
potentially undergoing ferroptosis supports chronic neuroinflammation mediated by 
microglia and endothelial-related blood brain barrier deficits, neither of which were 
detected in this study. Previous investigations of cortical tissue from the DLF in CTE 






investigation into the cellular and molecular profile of white matter microglia in 
CTE20,51,236. Future studies isolating microglia, neurons, and endothelial cells should be 
performed for in depth transcriptional profiling of these under sampled cell types, as 
completed previously in other studies using human brain tissue 235,237. Furthermore, 
additional studies specifically isolating astrocyte nuclei for sequencing may add depth to 
these aforementioned findings, as demonstrated in previous snRNA-seq analyses238.  
Chapter IV: Single-nucleus Transcriptomic Analysis of Alzheimer’s Disease White 
Matter  
Alzheimer’s disease (AD) is the most common neurodegenerative disease and 
presents with known white matter atrophy and axonal loss. Similar to CTE, AD white 
matter changes on a transcriptional level have not been characterized. Furthermore, there 
has been no transcriptomic comparison between CTE and AD white matter.  
In Chapter IV, dorsolateral frontal white matter cell nuclei from individuals with  
neuropathologically confirmed Braak VI AD and eight sex-, age-, and RIN- matched 
controls were sequenced (n = 4) (Appendix Figure 2b-d). By performing snRNA-seq 
transcriptomic analysis in the white matter at the depth of the dorsolateral frontal sulcus, 
our study identified greater numbers of astroglia in AD, an upregulation of AD astrocyte-
specific gene transcripts associated with neuroinflammation, fewer OLs in AD, greater 
numbers of OPCs in AD, and increased numbers of disease-associated microglia in AD. 
The identification of more astroglia in AD with an upregulation of gene transcripts 






sites, such as the subcortical dorsolateral frontal white matter, which have been shown to 
be particularly vulnerable to cortical p-tau load107. Fewer OLs and more OPCs in AD 
may suggest myelin loss and a failure to remyelinate. Greater numbers of disease-
associated microglia in the context of our other findings supports white matter 
inflammation and neurotoxicity as factors in AD progression.  
 Limitations of the AD to control comparison analysis include RHI exposure of 
AD subjects, missing cause of death information for AD, subject matching to control 
subjects from Chapter III, lack of symptom information for AD samples, and AD subject 
number. AD subjects, taken from the UNITE Brain Bank, had some level of RHI 
exposure during life. While none of the subjects were diagnosed with co-morbid CTE or 
any other neurodegenerative disease (Appendix Table 4), RHI exposure is a confounding 
factor in this study. Additionally, AD subjects were missing cause of death information, 
although all AD subjects were examined neuropathologically and found to have no 
comorbid neurological disease or injury (Appendix Table 4). Although this dissertation 
discusses the association of this study’s brain region to depression symptoms in CTE and 
cognitive deficit symptoms in AD, clinical information was not available for AD 
subjects. Samples were chosen based on best fit for snRNA-seq analysis (age, PMI, RIN, 
AD diagnosis, no comorbid disease diagnosis, and available matching controls). Finally, 
compared to control subjects, AD subjects had a significantly lower PMIs than controls 
(Appendix Figure 2c). However, previous work has cast doubt on the importance of PMI 






It remains to be determined if findings from this chapter would occur in other 
stages of AD, as all of the AD subjects (all Braak VI) from this study had severe p-tau 
pathology. Additionally, it is unknown whether these findings are exclusive to the U-
fibers of the dorsolateral frontal cortex. Determining whether the molecular and cellular 
differences identified in this study correlate with disease stage and whether the findings 
are region-specific will be critical for improving disease diagnosis by potentially adding a 
layer of specificity to each disease stage. Furthermore, determining which molecular 
differences persist throughout disease progression and which differences appear at later 
stages may be important for developing pharmacotherapies. Next steps for this analysis 
should include generating single-cell transcriptomic profiles from additional subjects 
with neuropathologically diagnosed AD, which will add confidence to the findings. 
Additional data sets with more subjects can be integrated with the data presented here, 
thus providing a more comprehensive single-cell profile of AD white matter.  
Synthesis of Findings 
A unifying hypothesis, further informed by Chapter II and III, in the pathogenesis 
of CTE is that RHI induces the disease through BBB damage. RHI, including concussive 
and subconcussive impacts, produces injury to the axons and small blood vessels of the 
brain, with resultant BBB dysfunction and persistent neuroinflammation that triggers the 
progressive accumulation of hyperphosphorylated tau protein (p-tau) aggregates. This 
hypothesis is supported by human pathological studies of acute concussive injury that 
show multifocal traumatic axonal injury, microglial activation, and microhemorrhage 






in the brain6,185,240–242. Furthermore, in some young individuals after RHI, perivascular 
hemosiderin-laden macrophages are associated with focal deposition of p-tau6,242, 
suggesting that microvascular damage is mechanistically linked to the development of p-
tau pathology. Neuroinflammation, blood brain barrier leakage, and hemosiderin-laden 
macrophages are also characteristic of the white matter in CTE2,13,20,185. Magnetic 
resonance imaging (MRI) has shown that iron deposits are present in multiple cortical 
and white matter locations after RHI and are associated with cognitive impairment243–245. 
Iron accumulation induces transcription of the ferritin genes FTH1 and FTL246 and also 
activates ferroptosis, a form of regulated cell death characterized by the iron-dependent 
accumulation of lipid hydroperoxides247. Specifically examining mature OLs, our data in 
Chapter III suggest that OL loss in CTE might occur through accumulation and storage of 
excess iron, as reflected by greater levels of iron histologically and the enrichment of 
transcripts encoding the intracellular ferritin proteins FTH1 and FTL, and widespread OL 
cell death, evidenced by reduced cell number and more abundant levels of transcripts 
encoding CRYAB, a protein involved in regulating apoptosis and protein aggregation, in 
OLs. Death of OLs reduces metabolic and functional support to neurons and leads to 
rapid myelin loss248,249. Furthermore, the observed lower levels in CTE tissue for 
transcripts encoding TF (which plays a role in the sequestration of additional iron from 
brain blood vessels250) and FA2H (which is implicated iron-related neurological disorders 
and may maintain axonal and myelin sheath integrity in normal conditions197,251–253) 
detected by bulk gene expression analysis support widespread iron trafficking and 






OL loss, like that observed in CTE, may result in functional deficits due to white 
matter tract dysfunction from myelin loss and the additional death of neurons in the 
cortex, apart from p-tau-mediated neuronal death, due to a lack of axonal metabolic 
support. Changes to white matter tract integrity due to iron-mediated OL death may 
influence the onset of depression symptoms and others observed in CTE40,42,64.  
The remyelination process after injury, which appears stunted in CTE, may play 
also a role in the loss of OLs in CTE white matter tissue and merits future study. In 
severe human brain injury, postmortem assessments of white matter lesions identified a 
reduction in OL number and an increase in OPC numbers, proliferating presumably for 
the purpose of remyelination after white matter injury254. In the data set from Chapter III, 
no OPC cell number increase was detected in the context of decreased OL numbers in 
CTE samples. This may suggest a potential disruption of the entire OL lineage, not 
restricted to mature, OLIG2-positive OLs as detected by normalized nuclei counts in the 
snRNA-seq analysis.  
Glial cell types like astrocytes and microglia are also implicated in white matter 
neurodegeneration in CTE. White matter astrocytes in CTE present with a 
neuroinflammatory transcriptional phenotype in Chapter III, but do not proliferate in 
number as has observed in the cortex of CTE, nor like that of white matter in AD, as 
determined by Chapter IV. This lack of proliferation in astrocytes in CTE is also affirmed 
in Chapter II and in a separate study of BA8/9 white matter in CTE61. While not 
increased in number, neuroinflammatory astrocytes express neurotoxic factors that may 






integrity. Additionally, in Chapter II, microgliosis of the white matter is observed in 
CTE, specifically in individuals with depressed mood symptoms compared to controls. 
Microgliosis was not identified in the samples from Chapter III. However, this may be 
explained by the lack of depression-state stratification in Chapter III. In AD, microglial 
alterations (both in increase of number and in larger area of processes) was observed 
compared to control samples in Chapter IV. Both white matter astrocytes and microglia 
in CTE compared to controls were found to express transcripts related to iron trafficking, 
further supporting infiltrating iron from white matter BBB damage as a source of cellular 
stress and cell death in CTE.  
The identification of widespread white matter glial changes, likely resulting from 
BBB disruption, in multiple cell types suggests that white matter pathology contributes to 
the etiology of both disease progression and symptoms in CTE. In an area strongly 
implicated in depression in Chapter II, white matter neuroinflammatory processes and, 
potentially subsequent, myelin loss was identified in samples with both depressed mood 
and CTE compared to non-depressed CTE samples. Though it is not certain whether the 
samples from Chapter III experienced depression, fundamental cellular and 
transcriptional changes were observed in several white matter cell types in DLF tissue, 
many of them neuroinflammatory and demyelinating. 
When comparing these findings to white matter in AD, the cellular and 
transcriptional profiles of AD suggest cortically dependent white matter degeneration, 
unlike CTE where cortical and white matter pathology may act simultaneously upon BBB 






however astrocytes in AD are increased in number when compared to control. This 
proliferation may be due to the widespread cell death observed in OLs, the most abundant 
cell type in control white matter snRNA-seq profiles. OLs in AD do not share the same 
iron dysregulation-related transcriptional profile as those in CTE, instead expressing 
transcripts related to cell stress and death, possibly due to widespread cortical pathology 
and neuronal death. OLs must maintain a certain number of connections to axons to 
survive. With increasingly severe neuronal death due to excitotoxicity and p-tau 
pathology, OLs could apoptose upon losing connections to live axons, resulting in 
demyelination and neuronal cell stress255. Both astrocytes and microglia, which were both 
increased in number in AD samples, clear myelin debris in an attempt to allow for 
remyelination, but often become reactive and gliotic in the presence of widespread cell 
death205,256,257. OPCs, which were increased in number in AD samples, may proliferate as 
a response to demyelination in an attempt to remyelinate, as observed in an AD animal 
model231. However, OPC differentiation can be inhibited by widespread myelin debris 
and neurotoxic factors, furthering cortical damage by leaving existing neuronal axons 
without the metabolic support of myelin258,259. As in CTE, widespread OL cell death may 
disrupt white matter tracts, influencing functional networks and leading to symptom 
presentation. While this study is a preliminary examination of white matter in AD, white 
matter cell death and associated symptoms may be influenced more by cortical pathology 







 These studies identify several cell types of interest, specifically OLs and 
astrocytes, that may be preferentially affected by the BBB damage caused by exposure to 
RHI in CTE. Additionally, several symptom profile-specific findings in CTE white 
matter suggest that certain differences between white matter brain regions may in part 
drive symptom profiles. Furthermore, certain similarities and differences between white 
matter changes in CTE and AD have been identified, further informing the etiology of 
white matter pathology and delineating the two neurodegenerative tauopathies. With 
limitations considered, the present findings provide a catalyst for understanding the 
relationship between gray and white matter pathology in AD and aid the future 
development of biomarkers for the diagnosis of CTE during life as well as potential 
targets for therapeutics that are specific to CTE that target iron accumulation and 







APPENDIX I - METHODS 
Methods for Chapter II 
These methods were adapted from a manuscript in preparation. 
Citation and author contributions are the same as listed in Chapter II.  
Sample Collection and Experimental Group Assignment 
Clinical neuropathologists from the Veterans Affairs-Boston University-
Concussion Legacy Foundation (VA-BU-CLF)/ Understanding Neurological Injury and 
Traumatic Encephalopathy (UNITE) Brain Bank dissected postmortem brain samples 
fixed in periodate-lysine-paraformaldehyde (PLP) from the Brodmann Area 25 (BA25) 
region from 55 individuals including 42 neuropathologically diagnosed with CTE and 13 
neuropathological controls, both with and without a history of depressed mood symptoms 
(Appendix Table 2). All individuals had a history of head trauma, and all but one (in the 
control group) had at least one year of exposure to repetitive head impacts (RHI). 
Experimental group assignment was based on the results of a comprehensive 
retrospective clinicopathological assessment by experienced clinicians. Specifically, 
group assignment of “depressed mood” or “non-depressed mood” for both the CTE and 
RHI-experienced control groups was defined by a binary answer of “yes” or “no” to 
depressed mood during the decedent’s last year of life in a questionnaire completed by 
respondents for the decedents upon brain donation to the Veterans VA-BU-CLF/UNITE 
Brain Bank55. Group assignment of depressed mood based on this questionnaire was 
chosen in place of other measures of depression (e.g. Geriatric Depression Scale260–263 






selection. Antidepressant medication group assignment were determined by medical 
records. Antidepressant medication included multiple forms of medications (e.g. SSRIs 
and SNRIs). Additional information regarding inclusion criteria and subject 
demographics is described in Subject Profiles for Chapter II.  
 All brains were examined across multiple regions, not including the BA25 brain 
region, by neuropathologists to assess neuropathology related to CTE, Alzheimer’s 
disease (AD), frontotemporal lobar degeneration, motor neuron disease, and other 
neurodegenerative disease. Discrepancies in neuropathological diagnosis were resolved 
by group discussion and consensus. Paraffin-embedded fixed brain tissue from each 
subject underwent a set of diagnostic stains for p-tau (AT8 and Bielschowsky stain), beta-
amyloid (Aβ), alpha-synuclein, and phosphorylated TDP-43 (pTDP-43)) in addition to 
luxol-hematoxylin-eosin (LHE) staining for myelin integrity visualization. Each subject 
also underwent a postmortem clinical assessment by a team of clinicians, including a 
detailed structured family history and examination of medical records. Clinical data were 
collected and managed using Research Electronic Data Capture (REDCap) electronic 
data capture tools hosted at Boston University, CTSI 1UL1TR00143057. Diagnosis of 
CTE and staging of disease severity was contingent on the presence of previously defined 
criteria2,63, particularly the presence of pathognomonic perivascular p-tau lesions at the 






Tissue Processing for IHC 
Blocks of fixed tissue from every sample were placed in an automated tissue 
processor (Leica ASP300S), processed, and embedded in paraffin (Leica EG1160) for 
sectioning. Tissue was cut on a microtome (Microm HM340E) at 20 µm, floated on a 42° 
C water bath, and placed on glass slides. Slides were dried overnight under a ventilation 
hood before placement in a 60° C oven for 30 minutes to remove excess paraffin before 
all IHC and histological staining (Appendix Table 1). 
IHC and Histological Staining Details 









This antibody allowed us to 
examine Aβ positive inclusions, 
which sometimes appear in 
CTE264.  
BioLegend 1:100,000 







This antibody allowed for the 
examination of aquaporin 4 
expression, linked to BBB 
dysfunction, in astrocytes after 
neurological insults 265,266. 






This stain sensitively detects 
NFTs, a hallmark feature of CTE. N/A Manual 
Anti-CD8 
(CD8) IHC This antibody allowed for the examination of the number of 
CD8+ regulatory and cytotoxic T-














This antibody allowed for the 
examination of astrocytes through 
the number and size of GFAP+ 
(astrocytic marker) astrocytes. 
Millipore 1:750 (Mouse) Leica BOND 
Anti-Iba1 
(IBA-1) IHC 
This antibody allowed for the 
examination of microglia through 
the number and size of IBA1+ 
cells (microglia/macrophages). 








Luxol fast blue dyes myelin, 
allowing for the visualization of 




This antibody allowed for the 
examination of the number of 
MAP2+ post-mitotic neurons, 
which comprise of most of the 
interstitial white matter 
neurons268. NeuN, a marker that 
labels all interstitial white matter 
neurons, was not usable in this 
tissue due to extended fixation 
time. 
BioLegend 1:50 







This antibody allowed us to 
examine pTDP43 positive 
inclusions, which sometimes 
appear in CTE58. 
Cosmo Bio. Co. 1:1,000 
(Mouse) Manual 
IHC BOND Staining 
Slides stained using the BOND RX system (Leica Biosystems) were heated to 90° 
C to remove all paraffin, given a peroxide block for 5 minutes, and exposed to either a 6 
pH or a 9 pH epitope retrieval solution (Leica Biosystems) for 5, 10, 20, or 30 minutes at 






minutes or 120 minutes), post-primary solution (10 minutes), polymer solution (10 
minutes), Fast Red or diaminobenzidine (DAB; 10 minutes), and hematoxylin (5 
minutes). Washes with Bond Wash solution (Leica Biosystems) also will follow the 
peroxide block, primary antibody solution, post-primary solution, and the polymer 
solution. Washes with deionized water occurred before and after chromogen, 
hematoxylin, and the final Bond Wash solution wash steps. All steps occurred at room 
temperature unless otherwise specified. Slides were manually dehydrated after staining 
with 95% EtOH, 100% EtOH, and xylene after completion of the antibody-specific 
customized protocols before coverslipping. All slides were coverslipped manually with 
Shandon Consul-Mount (Thermo-Scientific). 
IHC Manual Staining 
Manually stained slides were immersed in successive baths of xylene, 100% 
EtOH, and 95% EtOH before a 30 minute incubation in methanol peroxide to block 
endogenous peroxides. Before blocking, slides were placed in 88% formic acid for 
epitope retrieval. Slides were placed in ScyTek Superblock for 5 minutes. Primary 
antibodies were applied, and slides were stored in a 4° C refrigerator overnight. Slides 
were placed in UltraTek Anti-Polyvalent Biotinylated Secondary Antibody (ScyTek) for 
30 minutes and UltraTek HRP (ScyTek) for 30 minutes before adding AEC chromogen 
(Novus Biologicals) until development of desired staining. Slides were covered in 
Aqueous Mount (ScyTek) media, set in a 60° C oven for 30 minutes, and coverslipped 







One slide from every case was stained using a previously documented protocol 
for Bielschowsky Silver Stain269. For LHE staining, slides were left in Luxol fast blue 
(LFB) solution overnight at room temperature after deparaffinization and hydration to 
distilled water. LFB staining was reduced using a solution of sodium sulfite and 
hydroquinone. Slides were counterstained with hematoxylin and placed in 2% acetic acid, 
1% ammonium hydroxide, and Eosin Y. Slides were dehydrated in graded alcohols, 
cleared in xylene, and coverslipped manually.  
Slide Visualization and Quantification 
Stained slides were digitally scanned using an Aperio ScanScope system with a 
Leica AT Turbo brightfield scanner at 20X magnification (Leica Biosystems), examined 
using Aperio eSlide Manager (Leica Biosystems), and quantified with Aperio 
ImageScope (Leica Biosystems) software, as performed previously20,50. Number of 
MAP2-immunoreactive cells was quantified using the HALO (Indica Labs) software 
system. White matter was digitally traced using Aperio ImageScope (Leica Biosystems) 
and HALO. Briefly described, the full white matter selection from a full slide scan from 
every subject was manually selected with a pen tool in both Aperio ImageScope and 
HALO. After isolating the full white matter selection, a negative pen tool was used to 
remove any tears, artifacts, or white matter areas with poor focus to prevent inaccuracies 
in quantification. Analysis algorithms were tuned specifically for identifying positively 






cellular quantifications, the total number of immunoreactive cells were divided by the 
total area of analysis to determine cell density. For quantification of overall staining 
and/or protein expression, total number of immunoreactive-/ LFB-positive pixels were 
divided by tracing area to determine density. Bielschowsky silver stain slides were not 
quantified. In one case, two BA25 tissue blocks from the same subject were provided by 
neuropathologists. In this case, a slide from both blocks was treated identically and 
quantified for every stain. The output from every quantification analysis for both slides 
from the same case was averaged to create one representative value for the subject for 
statistical analysis. 
Statistical Analyses 
Pairwise comparisons were made by t-tests (with or without Welch’s correction) 
or Mann-Whitney tests, with normality determined by D’Agostino & Pearson tests. 
Comparisons between more than two groups was made by ANOVA (or Brown-Forsythe 
ANOVA when Brown-Forsythe tests was significant) or Kruskal-Wallis tests. Outliers 
were removed as necessary by Grubb’s test (P = 0.05). Factors contributing to suicide in 
CTE was analyzed by binary logistic regression, with death by suicide as the dependent 
variable. As controls differed in age from CTE groups (Supplementary Table 4), age was 
corrected for when significant with ANCOVAs. All analyses were completed using Prism 
8 (GraphPad) or SPSS (IBM) software. Results were considered statistically significant at 






Methods for Chapter III 
These methods were adapted from an article in review. 
Citation and author contributions are the same as listed in Chapter III.  
Isolation of Nuclei  
All tissue was dissected into 30 mg sections from frozen dorsolateral frontal white 
matter (Brodmann Area 8/9) with a scalpel blade and stored at -80° C. On the day of 
single-nucleus encapsulation, tissue was placed in a 7 mL dounce with ice cold buffer 
(0.5M sucrose, 2M KCl, 1M MgCl2, 1M Tricine-KOH pH 7.8, spermine, spermidine, 
DTT, RNasin, H2O) and dounced with a tight pestle ten times to mechanically dissociate 
and homogenize the tissue. To further dissociate the tissue, 5% IGEPAL-CA630 was 
added to the homogenate and dounced 5 times. The homogenate was then strained 
through a 40 μm cell strainer (VWR) on ice. Then, 5 mL of 50% iodixanol was added to 
the homogenate and mixed. In a 13 mL ultraclear ultracentrifuge tube, 1 mL of 40% 
iodixanol was added with 1mL of 30% iodixanol carefully layered on top, followed by 10 
mL of the tissue homogenate. The tissue was then ultracentrifuged in a swing-bucket 
rotor at 10,000xg for 18 minutes. Following ultracentrifugation, the 35% iodixanol layer 
was collected and the nuclei were counted. Nuclei were diluted with 30% iodixanol to 
90,000 nuclei/mL for inDrops chip loading. Nuclei were isolated for inDrops using a 
previously described method113. 
Droplet-Based snRNA-seq with inDrops and Sequencing 
Isolated nuclei were delivered to the inDrops single cell core facility at Harvard 






per subject by encapsulating each nucleus in a hydrogel containing barcodes and unique 
molecular identifiers (UMIs). Nuclei were lysed and each free mRNA molecule was 
reverse transcribed to cDNA and labeled with a barcode and UMI, which enables 
mapping that specific cDNA molecule to its particular cell of origin and ensures that 
specific amplified sequence is counted only once bioinformatically111,115, thus avoiding 
the production of potential PCR amplification-generated artifact. This process produced 
labeled cDNA molecules for all 16 samples. Sample cDNA was delivered to the 
Biopolymers Facility at Harvard Medical School. Sample quality was assessed by Agilent 
Tapestation. Samples with excess primer dimer contamination were filtered by 
SPRIselect size selection (Beckman Coulter, B23317), followed by pooling of libraries 
and dilution for sequencing. Pooled samples were sequenced on the Illumina NextSeq500 
at an average of 40,000 reads per nucleus barcode, approximately 360,000,000 reads per 
sample. 
Pre-Processing snRNA-seq Sequencing Data 
The Biopolymers Core Facility delivered Binary Base Call (BCL) files for each 
sequencing run. The inDrops single cell method requires four primers to completely 
capture and de-multiplex a cDNA molecule. The first primer captures the transcript, the 
second captures part of the single cell barcode, the third captures the library or sample 
index, and the fourth captures the rest of the single cell barcode, the UMI, and the polyT 
tail. BCL files produced by sequencing were converted to 4 FastQ files, one per inDrops 






that followed the expected inDrops index structure, described above. Reads that passed 
structure filtering were de-multiplexed based on library index, resulting in reads by 
sample of origin, i.e., subject. Abundant barcodes were identified and sorted so that each 
cDNA from a single nucleus was grouped together. During sample preparation, every 
cDNA molecule was labeled with a UMI, which avoids any single molecule being 
counted more than once due to PCR amplification. After each read was de-multiplexed, 
thus assigning reads to nucleus of origin and nuclei to sample of origin, reads were 
aligned with bowtie/1.1.1 to an edited version of the GRCh38.97 reference genome so 
that all exonic and intronic reads were counted. Aligned reads were quantified and a UMI 
count matrix was produced for each sample. De-multiplexing was executed following the 
inDrops analysis pipeline (https://github.com/indrops/indrops).  
Quality Control and Cell Filtering 
UMI count matrices for each subject were loaded into R version 3.6.1 using the 
Scater R package270. Control samples were combined and CTE samples were combined 
to generate two separate objects with the R package Seurat version 3.1190. The Seurat 
object filtration process included excluding nuclei with fewer than 400 genes and more 
than 2,500 genes, which limited our analysis to nuclei with high-quality RNA. We also 
removed nuclei with more than 1% mitochondrial genes, which excluded nuclei that were 
potentially undergoing lysis due to sample preparation. To identify cell types and/or cell 
states in the data set, we constructed an unbiased k-nearest neighbor graph based on top 






optimization algorithm217 to group the cell nuclei into clusters based on gene expression 
similarities and produce a two-dimensional t-distributed stochastic neighbor embedding 
(tSNE) projection190,218. The tSNE algorithm provides an unbiased similarity clustering of 
nuclei by gene expression, shaped by parameters selected prior to analysis, such as 
number of principal components, number of highly variable genes, and resolution198. 
Through iterative parameter space testing116–118,121,122,198, we settled on values that 
resulted in stable clustering with high intercluster distance and low intracluster distance, 
meaning, on average, nuclei in the same cluster were more similar to each other than to 
nuclei in a different cluster. Specifically, we chose 23 principal components and a 
resolution of 0.8 for input parameters (Appendix Figure 1h). The Seurat 2 objects were 
then normalized and log-transformed using Seurat’s implementation of SCTransform and 
integrated using Seurat’s implementation of canonical correlation analysis (CCA) to 
correct for batch effects190,191. Integration was performed to integrate control and CTE 
samples, thus creating a single Seurat object for downstream analyses, “CTE.combined.”  
Cell Clustering 
The single integrated Seurat object, “CTE.combined,” was scaled using ScaleData 
and a principal component analysis (PCA) was performed for initial dimensionality 
reduction. An Elbow Plot was produced to determine the number of principal 
components to be used for further analyses (Appendix Figure 1h). Based on the Elbow 
Plot, 23 principal components were used. Using RunTSNE, FindNeighbors, and 






dimensional tSNE projection. This process included constructing an unbiased k-nearest 
neighbor graph based on top principal components followed by a Jaccard similarity step 
and the Louvain modularity optimization algorithm. Parameters, including resolution, 
were varied over several iterations to identify a tSNE that was in agreement with 
published human white matter brain data116 and that represented nuclei clusters that were 
consistently present over several iterations. Nuclei distances were also considered in 
order to increase intercluster distances and decrease intracluster distances, thereby 
producing clusters in which nuclei in the same cluster were more similar to each other 
than to nuclei in a different cluster. The final tSNE projection used was produced at 
resolution 0.8 and included 18 transcriptionally distinct nuclei clusters.  
Cell-Type Annotation and Sub-clustering 
FindAllMarkers and FindMarkers were used to identify cluster-specific 
genes116,118,121,122. Top genes for each cluster and the expression of top genes on the tSNE 
were used to identify clusters (Figure 9c, Appendix Figure 3, Supplementary Table 2). To 
further analyze specific cell-types, clusters from the primary tSNE were subset. 
SubsetData was used to isolate nuclei from a specific cell-type, and ScaleData, RunPCA, 
RunTSNE, FindNeighbors, and FindClusters were performed on the subset data to 
produce a new Seurat object for each cell-type.  
Cell-Type-Specific Gene Expression Analysis and Differential Gene Expression Analysis 
To determine the marker genes (the genes that make a specific cluster unique 






FindMarkers was used. Differential gene expression analysis was performed using 
Seurat’s implementation of MAST271. For bulk analysis, all CTE clusters were analyzed 
against all control clusters. For cell-type-specific analysis, one cluster from CTE was 
analyzed against the corresponding cluster from control. Bonferroni-corrected P-values ≤ 
0.05 were taken, and genes with a fold change of at least 0.01 were considered.  
Technique Correlation Analysis 
To determine whether findings across experimental methods were significantly 
correlated, normalized nuclei counts identified by snRNA-seq transcriptomic analysis 
were plotted against the number of OLIG2+ nuclei identified by smFISH. Each dot on the 
plot represented a single human subject (Control: Red, CTE: Teal), with snRNA-seq 
transcriptomic analysis providing the x-coordinate value and smFISH providing the y-
coordinate value. A Shapiro-Wilk test was performed to determine normality of the data 
set and a Pearson correlation coefficient was produced to determine correlation and 
statistical significance.  
Gene Ontology Analysis 
The set of all genes significantly differentially expressed between CTE and 
control nuclei (FDR < 0.05) within astrocyte cell-types were used as query inputs for 
gene ontology analyses by PANTHER Classification System v14.1 
(www.pantherdb.org)199 to identify over-represented gene modules. Modules were 
assigned by PANTHER's statistical overrepresentation test in which a binomial test was 






expressed in a certain cell-type) to determine if a known biological pathway had non-
random linkage within the query set. All identified modules derived from PANTHER's 
"GO biological process complete" gene annotation and only those with a false-discovery-
rate-corrected P-value ≤ 0.05 were considered.  
Cell-Type Representation Analysis 
To determine whether any cluster of nuclei was increased or decreased in CTE 
subjects, compared to control subjects, numbers of nuclei in each cluster were normalized 
to the sample with the largest number of nuclei (see methods in118, Supplementary Table 








Normalized cell numbers for each cell-type and sample were then compared 
between experimental conditions using a two-tailed Mann-Whitney U test (FDR-
corrected for multiple comparisons).  
Iron Staining 
Fresh frozen tissue stored at -80° C was adhered to cryostat compatible metal 
chucks using Optimal Cutting Temperature compound (Leica) and allowed to acclimate 
to a -17° C cryostat (Leica CM3050 S) for 1 hour before cutting. Tissue was cut at 16 µm 






60° C oven for 15 minutes after cutting for tissue adherence and placed directly in room 
temperature 10% formalin for 1.5 hours for fixation. Slides were then dehydrated in 50%, 
70%, and 100% ethanol baths for 2 minutes each before being heated in a 60° C oven for 
30 minutes to dry slides for room temperature storage. Prussian blue staining, which 
produces a dark blue pigment on all ferrous iron present in the tissue, was completed on 
all slides with hematoxylin and eosin counterstain. Prussian blue stained slides were 
placed in a solution of 0.06N Hydrochloric acid and Potassium Ferricyanide for 1 hour at 
room temperature before a wash in 1% Acetic Acid and hematoxylin and eosin 
counterstains.  
Immunofluorescence 
Fresh frozen tissue stored at -80° C was adhered to cryostat compatible metal 
chucks using Optimal Cutting Temperature compound (Leica) and allowed to acclimate 
to a -17° C cryostat (Leica CM3050 S) for 1 hour before cutting. Slides used for IF 
staining were cut at 10 µm using a CryoJane Tape Transfer System (Leica). Slides were 
placed in ice cold formalin for 15 minutes after cutting, rinsed in PBS, and allowed to dry 
fully under a ventilation hood. Slides were then stored at -80° C and allowed to thaw at 
4° C before being used for manual IF staining. Anti-mouse GFAP (1:1,000; Millipore) 
and anti-rabbit CD44 (1:2,000; Abcam) antibodies were used for double-labeled IF 
staining. Slides were placed in 3 changes of 0.01% Triton for 5 minutes for tissue 
permeabilization, blocked in 3% normal donkey serum for 30 minutes, heated at 95° C in 






with a primary antibody. A donkey anti-mouse or a donkey anti-rabbit secondary was 
used at a 1:500 concentration with 1% Normal Donkey Serum for one hour at room 
temperature. Fluorescent labeling was conducted using Opal 480 (GFAP) and Opal 570 
(CD44) dyes (1:150; Akoya Biosciences) for 10 minutes at room temperature, followed 
by 5 minutes of DAPI counterstaining.  
Immunohistochemistry 
Tissue cutting, fixation, and slide preparation were completed using the same 
method as iron staining. All brightfield immunohistochemistry was completed using 
individually optimized protocols using Research Detection Kits on a BOND RX (Leica) 
system, using the same method described for Chapter II (Appendix I, Methods). 
Antibodies used on the BOND RX included: anti-rabbit PDGFRα (1:100; Abcam), anti-
rabbit OLIG2 (1:100; Millipore), and anti-rabbit IBA1 (1:1,000, Wako).  
Single Molecule Fluorescent mRNA In Situ Hybridization 
Tissue cutting, fixation, and slide preparation were completed using the same 
method as iron staining. Single-molecule fluorescent mRNA in situ hybridization was 
conducted using RNAscope (Advanced Cell Diagnostics) probes and kits optimized for 
use on a BOND RX (Leica) system. All slides were treated with a 30 minute protease 
step, 1 minute of hybridization, and 10 minutes of epitope retrieval (9 pH) at the 
beginning and end of the protocol. Concentration of Opal dyes (480, 570, 690 
fluorophores; Akoya Biosciences) for fluorescent labeling were diluted at 1:1,500 in TSA 






according to manufacturer's instructions. Probes used for multiplex staining included 
OLIG2/FTH1/CRYAB/DAPI and GFAP/CD44/BCL6/DAPI.  
Slide Visualization and Quantification 
All slides used for iron staining, IF, IHC, and smFISH were scanned at 40X using 
custom protocols on a Vectra Polaris (Akoya Biosciences) or at 20X using standard 
protocols on a Leica AT Turbo (Leica Biosystems; only IBA1 slides) whole slide scanner 
and quantified using custom protocols on HALO (Indica Labs) software. One slide, per 
stain, from every subject was scanned and analyzed. For IHC analysis, HALO was 
manually trained to identify the color of the antibody-positive chromogen or dye (DAB, 
fast red, or Prussian Blue) and counterstain (hematoxylin). By manually adjusting HALO 
settings on stain color identification and expected inclusion shape and size, chromogen- 
or dye-positive inclusion counts and/or positively staining area measurements were 
generated for the selected tissue analysis area. Masks representing the HALO analysis 
were produced in order to determine the accuracy of all analyses. For IF and smFISH, 
HALO is programmed to detect the Opal dyes and DAPI (Akoya Biosciences) used in 
these experiments innately. For IF analysis, HALO settings on Opal dye intensity were 
adjusted to accurately map observed GFAP and CD44 expression. HALO produced 
values representing the area of GFAP or CD44 positivity based on the manually adjusted 
positivity settings in the selected tissue analysis area. For RNAscope analysis, HALO 
settings on dye intensity and inclusion shape were adjusted to identify and map DAPI 






encompass Opal dye-positive inclusions inside of nuclei and/or within a 5 µm radius 
from the center of nuclei. This value was selected to best represent measured cell bodies 
observed in our OLIG2 IHC and GFAP IF staining, as measured by the HALO length 
measuring tool. Inclusions detected within the set parameters were measured by area. 
Masks representing the HALO analysis were produced in order to determine the accuracy 
of all analyses. All analyses were conducted in 1 mm2 sections of the white matter tissue 
adjacent to the depth of a cortical sulcus, in order to best represent the tissue location 
analyzed by snRNA-seq, unless otherwise specified. Full white matter analyses were 
conducted on OLIG2 and PDGFRα IHC staining.  
Statistical Analyses 
Statistical analyses were performed in either R version 3.6.1 or GraphPad Prism 
8. P-values were considered significant if α ≤ 0.05. Gene expression statistical analyses 
were performed in R using MAST and Bonferroni correction for multiple comparisons271. 
To identify an increase or decrease in the number of normalized nuclei between 
conditions, a Mann-Whitney U test was performed, and P-values were FDR-corrected for 
multiple comparisons as previously described118. IHC, IF, and smFISH quantification 
was performed using a one-tailed Student’s t-test or one-tailed Mann-Whitney U test, as 
determined by Shapiro-Wilk normality testing of each analysis. One-tailed tests were 
performed on all imaging analyses to determine the validity of snRNA-seq findings of 
significant gene expression and/or nuclei number differences between CTE and control. 






determined by tissue availability. Results were considered statistically significant at α ≤ 
0.05.  
Code Availability 




The snRNA-seq and in situ validation data that support the findings of this study 
are available from the corresponding author. Raw and processed snRNA-seq data are 
available at Gene Expression Omnibus (GEO) under accession number GSE155114.  
Methods for Chapter IV 
Single-Molecule Fluorescent mRNA In Situ Hybridization 
No OLIG2/FTH1/CRYAB/DAPI multiplex staining was completed for AD 
subjects in Chapter Four. All other smFISH staining methods for Chapter IV were 
identical to those of Chapter III. 
Additional Methods 
All other methods for Chapter IV are identical to those described above for Chapter 
III. Raw and processed snRNA-seq data will be published to GEO at the time of the 






present in Appendix III (Appendix Figure 2, Appendix Figure 11). IBA1 staining was 






APPENDIX II – SUBJECT PROFILES 
Subject Profiles for Chapter II 
This section was adapted from a manuscript in preparation. 
Citation and author contributions are the same as listed in Chapter II. 
 
Groups for this study consist of CTE-positive subjects with and without 
depression and RHI-exposed controls with and without depressed mood (Appendix Table 
2). Groups were not age- or McKee Stage-matched prior to selection. PLP-fixed tissue 
sections from BA25 were acquired from the Veterans Affairs-Boston University-
Concussion Legacy Foundation (VA-BU-CLF)/ Understanding Neurological Injury and 
Traumatic Encephalopathy (UNITE) Brain Bank. Prior to sample collection, all subjects 
underwent a neuropathological evaluation by clinical neuropathologists using established 
protocols to detect any neurological disease or tissue integrity deficits47. RHI controls had 
no symptomatic head injury or neurological disease. Inclusion criteria, at the time of 
sample selection, included availability of fixed white matter samples from BA25, no 
comorbid neurodegenerative disease (in the case of CTE samples), no neurodegenerative 
disease (in the case of RHI-experienced controls), available data regarding depressed 










Appendix Table 2. Description of subject demographics for Chapter II. All values are Mean ± SD.  
 
Subject Profiles for Chapter III 
This section is adapted from a pre-published article. 
Citation and author contributions are the same as listed in Chapter III.  
 
CTE brain tissue samples of fresh frozen dorsolateral frontal (DLF) cortex 
(Brodmann Area 8/9; BA8/9) were selected based on a neuropathologically verified 
diagnosis of McKee Stage II or Stage III CTE without evidence of co-morbid neurologic 
or neurodegenerative disease from the VA-BU-CLF/UNITE Brain Bank at VA Boston. 
Brain tissue samples neuropathologically determined to have no neurological or 
neurodegenerative disease from the National Posttraumatic Stress Disorder (PTSD) brain 






analysis are identical to the Understanding Neurological Injury and Traumatic 
Encephalopathy (UNITE) Brain Bank, were selected as controls. Subject ages were not 
significantly different (Control: 55.6 ± 7.5 years; CTE: 55.9 ± 10.7 years; P = 0.94, two-
tailed Mann-Whitney U test) (Appendix Figure 1b). Subject PMI was not significantly 
different (Control: 31.7 ± 9.7 hours; CTE: 35.3 ± 10.2 hours; P = 0.70, two-tailed Mann-
Whitney U test) (Appendix Figure 1c). Subject RIN values were not significantly 
different (Control: 6.4 ± 1.7; CTE: 6.8 ± 1.7; P = 0.56, two-tailed Mann Whitney U test) 
(Appendix Figure 1).  
For the snRNA-seq analysis, the subcortical white matter was dissected from the 
tissue blocks and included both deep white matter and U-fibers. For the in situ analysis, 
DLF tissue with both cortical and white matter tissue adjacent to the white matter block 
taken for snRNA-seq analysis was isolated (Appendix Figure 1a). RIN number 
determination was completed according to manufacturer instructions using a Bioanalyzer 






























sulcus), solid rectangle represents a region taken for all in situ validation (gray and white matter adjacent to 
the region taken for snRNA-seq). GM: gray matter, WM: white matter, CS: cortical sulcus. b. Scatter plot 
with bar for each subject by age (n = 8 per condition, median of CTE = 54.5 years, median of control = 52.0 
years, P = 0.94, two-tailed Mann-Whitney U test, U = 31.0). c. Scatter plot with bar for each subject by 
postmortem interval (PMI) (n = 8 per condition, median of CTE = 34.0 hours, median of control = 32.75 
hours, P = 0.70, two-tailed Mann-Whitney U test, U = 25.0). d. Scatter plot with bar for each subject by RNA 
integrity number (RIN) value (n = 8 per condition, median of CTE = 7.1, median of control = 6.4, P = 0.56, 
two-tailed Mann-Whitney U test, U = 26.0). e. tSNE projection colored by number of genes present in each 
nucleus. f. tSNE projection colored by number of unique molecular identifiers (UMIs) present in each 
nucleus. g. (left) Violin plots for the number of genes expressed in each nucleus for control and CTE subjects. 
(right) Violin plots for the number of UMIs present in each nucleus for control and CTE subjects. h. Elbow 
plot for the amount of variance produced by each principal component. Principal components (PCs) from 1 
to 30 on the x-axis and standard deviation on the y-axis. All data was presented in Mean ± S.E.M. 
Subject Profiles for Chapter IV 
All control cases from Chapter III were selected for comparison to 4 AD cases for 
the Chapter IV analysis (Appendix Table 4.). Diagnosis of AD was in accordance with 
the National Institute on Aging—Alzheimer’s Association  (NIAA) criteria for AD and 
Braak staging3,21,97. AD subjects were selected based on a neuropathologically verified 
diagnosis of AD Braak Stage VI without any co-morbid neurodegenerative disease and 
availability of fresh frozen from DLF cortex (BA8/9) from the UNITE Brain Bank 
(Appendix Figure 2a). Control subjects were age-, RIN-, and sex-matched (all males) to 
AD samples and were neuropathologically confirmed to be free of any neurodegenerative 
disease or abnormalities. Fresh frozen tissue from the National Posttraumatic Stress 
Disorder (PTSD) Brain Bank was collected from control subjects from the DLF cortex 
(BA8/9). For the snRNA-seq analysis, the subcortical white matter was dissected from 
the tissue blocks and included both U-fibers and deep white matter. For the in situ 
analysis, a section of BA8/9 tissue with both cortical and white matter tissue adjacent to 
the white matter block taken for snRNA-seq analysis was isolated (Appendix Figure 2a). 






years; P = 0.0742, two-tailed Student’s t-test) (Appendix Figure 2b). Subject PMI was 
significantly different (Control: 31.7 ± 9.7 hours; AD: 10.95 ± 7.3 hours; P = 0.0054, 
two-tailed Student’s t-test) (Appendix Figure 2c). Subject RIN values were not 
significantly different (Control: 6.4 ± 1.7; AD: 7.4 ± 0.4; P = 0.3231, two-tailed Student’s 
t-test) (Appendix Figure 2d). RIN number determination was completed according to 














































































































































































































































































































































































































































































































































































































































































































































































sulcus), solid rectangle represents a region taken for all in situ validation (gray and white matter adjacent to 
the region taken for snRNA-seq). GM: gray matter, WM: white matter, CS: cortical sulcus. b. Scatter plot 
with bar for each subject by age (n = 8 (Control), n = 4 (AD), P = 0.07, two-tailed Student’s t-test, t(10) = 
1.993). c. Scatter plot with bar for each subject by postmortem interval (PMI) (n = 8 (Control), n = 4 (AD), 
P = 0.0054, two-tailed Student’s t-test, t(10) = 3.536). d. Scatter plot with bar for each subject by RNA 
integrity number (RIN) value (n = 8 (Control), n = 4 (AD), P = 0.32, two-tailed Student’s t-test, t(10) = 
1.039). e. tSNE projection colored by number of genes present in each nucleus. f. tSNE projection colored 
by number of unique molecular identifiers (UMIs) present in each nucleus. g. (left) Violin plots for the 
number of genes expressed in each nucleus for control and AD subjects. (right) Violin plots for the number 
of UMIs present in each nucleus for control and AD subjects. h. Elbow plot for the amount of variance 
produced by each principal component. Principal components (PCs) from 1 to 30 on the x-axis and standard 















(blue) in control and CTE (top) and the same images with masks (bottom) to demonstrate how nuclei and 
BCL6 positivity are identified. Scale bar (top-left, white): 50 µm. 
Supplementary Table Legends 
 
Supplementary Table 1. Single-nucleus RNA-seq quality control for Chapter III 
Supplementary Table 2. Cell-type marker genes for Chapter III 
Supplementary Table 3. Differential gene expression analysis for Chapter III 
Supplementary Table 4. Gene ontology for Chapter III 
Supplementary Table 5. Normalized nuclei counts for Chapter III 
Supplementary Table 6. Control counts matrix for Chapter III 
Supplementary Table 7. CTE counts matrix for Chapter III 
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